



HHS Public Access

Author manuscript

Cell Rep. Author manuscript; available in PMC 2023 August 18.

Published in final edited form as:

Cell Rep. 2022 December 13; 41(11): 111822. doi:10.1016/j.celrep.2022.111822.

A specific Argonaute phosphorylation regulates the binding to microRNAs during *C. elegans* development

Miguel Quévillon Huberdeau^{1,2}, Vivek Nilesh Shah^{1,2}, Smita Nahar³, Julia Neumeier⁴, François Houle^{1,2}, Astrid Bruckmann⁴, Foivos Gypas³, Kotaro Nakanishi^{5,6}, Helge Großhans^{3,7}, Gunter Meister⁴, Martin J. Simard^{1,2,8,*}

¹CHU de Québec-Université Laval Research Center (Oncology Division), Quebec City, Quebec, G1R 3S3, Canada

²Université Laval Cancer Research Centre, Quebec City, Quebec G1R 3S3, Canada

³Friedrich Miescher Institute for Biomedical Research, 4058 Basel, Switzerland

⁴Regensburg Center for Biochemistry (RCB), Laboratory for RNA Biology, University of Regensburg, 93053 Regensburg, Germany

⁵Department of Chemistry and Biochemistry, The Ohio State University, Columbus, OH 43210, USA

⁶Center for RNA biology, Columbus, OH 43210, USA

⁷University of Basel, 4056 Basel, Switzerland

⁸Lead contact

SUMMARY

Argonaute proteins are at the core of the microRNA-mediated gene silencing pathway essential for animals. In *C. elegans*, the microRNA-specific Argonautes ALG-1 and ALG-2 regulate multiple processes required for proper animal developmental timing and viability. Here, we identified a phosphorylation site on ALG-1 that modulates microRNA association. Mutating ALG-1 serine 642 into a phospho-mimicking residue impairs microRNA binding and causes embryonic lethality and post-embryonic phenotypes that are consistent with alteration of microRNA functions. Monitoring microRNA levels in *alg-1* phosphorylation mutant animals reveal that microRNA passenger strands increase in abundance but are not preferentially loaded into ALG-1, indicating that the miRNA binding defects could lead to microRNA duplex accumulation. Our genetic and biochemical experiments support the protein kinase A (PKA) KIN-1 as the putative kinase that phosphorylates ALG-1 serine 642. Altogether, our data indicate that PKA triggers the ALG-1 phosphorylation to regulate its microRNAs association during *C. elegans* development.

*Correspondence: Martin.Simard@crchudequebec.ulaval.ca.

AUTHOR CONTRIBUTIONS

Conceptualization, M.Q.H. and M.J.S.; Methodology, M.Q.H., V.N.S., S.N., A.B., F.G., K.N., H.G., G.M. and M.J.S.; Investigation, M.Q.H., V.N.S., S.N., J.N., F.H., A.B., F.G. and K.N.; Writing – Original Draft, M.Q.H. and M.J.S.; Writing – Review & Editing, M.Q.H., V.N.S., S.N., J.N., F.H., A.B., K.N., H.G., G.M. and M.J.S.; Funding Acquisition, K.N., H.G., G.M. and M.J.S.; Supervision, H.G., G.M., and M.J.S..

DECLARATION OF INTEREST

The authors declare no competing interests.

Keywords

miRISC; ALG-1; Protein Kinase A; PKA; KIN-1; post-translational modification; gene regulation

INTRODUCTION

MicroRNAs (miRNAs) were identified in *C. elegans* as potent regulators of developmental timing¹⁻³ and since then, have been shown to regulate a wide range of cellular processes in animals and plants⁴⁻⁶. MiRNAs are ~22 nucleotide (nt) long RNAs, which are typically produced by RNA polymerase II and a successive processing by Drosha and Dicer^{7,8}. The resulting mature miRNA duplex associates with an Argonaute (AGO) protein, which is held in an open conformation, and the closing of the structure triggers the unwinding of the duplex followed by the ejection of the passenger strand, also called miR*⁹⁻¹¹. The discarded strand is then subjected to degradation by exonucleases¹²⁻¹⁴. In many cases, there is a preference for a specific arm of the duplex to be loaded into AGO (originating from either the 5' or the 3' of the precursor miRNA), leading to a disproportionate number of copies for one of the two strands in cells. Although less abundant, specific miR* can be loaded into AGO and repress mRNA containing target sites, suggesting that some of them might be functional¹⁵.

The association between the miRNA and the AGO protein form the core of the miRNA-induced silencing complex (miRISC). Typically, the miRNA guides the miRISC to the 3' untranslated region (UTR) of mRNAs and binds sequences that are partially complementary, which leads to translational repression and destabilization of the target^{16,17}. The two miRNA-specific AGOs in *C. elegans* are ALG-1 and ALG-2^{18,19}; orthologous to the human AGO1-4. A third *C. elegans* AGO, ALG-5, also binds a small subset of miRNAs and is primarily expressed in the germline²⁰. AGOs are bilobed proteins composed of six domains: the N, L1, PAZ, L2, MID and PIWI²¹. The N domain serves as a wedge to unwind the miRNA duplex, during the loading step, while the PAZ and the MID domains bind the 3' and the 5' ends of the miRNA, respectively. The L1 linker between the N and PAZ domains and the L2 linker between the PAZ and MID domains, contribute to the structural stability of the RISC. The C-terminal PIWI domain resembles RNase H proteins²² allow the cleavage (or slicing) of target RNA that have an extended complementarity. In humans, AGO2 and AGO3 are slicer competent²³⁻²⁵. In *C. elegans*, the slicing activity of ALG-1 and ALG-2 was shown to be implicated in the production of functional miRISC²⁶. The PIWI domain also contains two tryptophan (W) binding pockets²⁷ which bind GW182 through its Glycine (G) Tryptophan (W) GW/WG repeats²⁸⁻³¹ that contribute to the removal of the poly(A) tail of targeted mRNA¹⁶.

AGO function is modulated by the addition and removal of post-translational modifications. In human cells, hypoxia increases the AGO2 hydroxylation and stabilizes it³². Upon hypoxic stresses, EGFR causes the AGO2 phosphorylation at tyrosine 393 (Y393) leading to defective maturation of specific miRNAs³³. The same residue can be dephosphorylated by PTPB1 and the inactivation of this phosphatase affects the function of H-RASv12-induced oncogenic miRNAs³⁴. Under cell stress, AGO2 localizes to stress granules where

it is poly ADP-ribosylated to relieve miRNA-mediated repression of translation³⁵. Beside these stress-induced modifications, the phosphorylation of AGO specific residues has been observed in normoxic conditions. The p38 MAPK and AKT3 pathways converge to phosphorylate the serine 387 (S387) to regulate AGO localization to processing bodies and drive translational repression^{36,37}. This specific modification was shown to regulate the association between AGO2 and LIMD1 and facilitate the AGO2 binding to GW182 protein TNRC6³⁸. Interestingly, the biological significance of S387 phosphorylation was highlighted by its implication in the control of dendritic spine growth and maturation³⁹. In addition to the regulation of localization and protein interactions, phosphorylation of specific AGO residues was also shown to affect the binding to miRNA and miRNA targets. The phosphorylation of tyrosine 529 (Y529) in the MID domain prevents the binding to small RNAs⁴⁰. Our recent systematic analysis of AGO phosphorylation identified a conserved serine/threonine phosphorylation cluster in the PIWI domain that is essential for miRNA-mediated gene silencing *in vivo* and showed that its hyper-phosphorylation impairs binding to miRNA targets⁴¹. The phosphorylation and de-phosphorylation of this cluster were shown to be mediated by the kinase CSNKA1 and the phosphatase PPP6C in human cells⁴². It was also reported that its phosphorylation impairs miRISC binding to miRNA targets and the lack of AGO2 phosphorylation on these residues leads to an expansion of the miRNA target repertoire⁴².

Here we report the phosphorylation of serine 642, a residue located in the MID domain of *C. elegans* ALG-1, which drastically reduces its ability to bind miRNAs. Mutation of this serine (S) into a phospho-mimicking negatively charged glutamate (E) leads to phenotypes reminiscent of animals completely depleted of *alg-1*. Developmental delays are observed in both the non-phosphorylatable alanine (A) and the phospho-mimicking glutamate mutants, indicating that this phosphorylation regulates key developmental events during animal growth. Our sequencing analysis further shows an miR* accumulation that are not bound to the ALG-1S642E mutant suggesting that the lack of miRNA-binding by ALG-1 leads to an accumulation of miRNA duplexes. Last, we show that the Protein Kinase A (PKA) *kin-1* interacts genetically with *alg-1*, and this was strongly suppressed by a non-phosphorylatable *alg-1(S642A)*. This data, along with the *in vitro* phosphorylation of serine 642, suggest that PKA regulates the miRNA-mediated gene silencing in *C. elegans* through the phosphorylation of ALG-1.

RESULTS

Assessment of a novel AGO phosphorylation site

Previously, we characterized *in vivo* effects of ALG-1 phosphorylation on a highly conserved serine/threonine cluster located on the surface of the PIWI domain⁴¹. Mass spectrometry analyses of immunopurified ALG-1 from *C. elegans* extracts identified an additional phosphorylation site on ALG-1 MID domain that had not yet been identified and characterized on AGOs (Figure S1A). To determine whether this phosphorylation event can affect the function of ALG-1 *in vivo*, we expressed transgenes carrying a non-phosphorylatable (alanine: A) or a phospho-mimicking (glutamate: E) mutation in an *alg-1* knockout strain *alg-1(gk214)* (hereafter called *alg-1(0)*). To determine whether these mutant

transgenes would rescue the loss of *alg-1*, we monitored the alae structure on young adult animals. During the transition from the fourth and final larval stage of *C. elegans* (L4) to young adult, seam cells exit the cell cycle, terminally differentiate and fuse in a syncytium. Differentiated seam cells secrete a cuticular structure known as the alae and the loss of *alg-1* function leads to an abnormal number of seam cells and defective cell fusion producing incomplete alae (gapped) or breaks along the structure^{18,19}. Rescue experiments showed that phospho-mimicking *alg-1(S642E)* transgenes were unable to rescue alae defects in *alg-1(0)* (Figure S1B) and, unlike the non-phosphorylatable *alg-1(S642A)* transgenes, they were unable to suppress larval arrest and sterility upon depletion of *alg-2* with RNA interference (RNAi) (Figure S1C). To determine whether non-phosphorylatable or phospho-mimicking variants of ALG-1 would impair *alg-1* function, when expressed from the endogenous *alg-1* loci, we produced these mutations in a wild-type background using CRISPR-Cas9 gene editing method. Mutation of this residue, on the endogenous loci of *alg-1*, revealed that *alg-1(S642E)* but not *alg-1(S642A)* displayed alae defects (Figure 1A). Likewise, a significant fraction of *alg-1(S642E)* mutant animals died at the larval to adult transition from vulva rupturing (Figure 1B); a phenotype that can be attributed to the impairment of the *let-7* miRNA family^{3,18,43,44}. These results support that the phosphorylation of serine 642 leads to the loss of *alg-1* function as the phospho-mimicking *alg-1(S642E)* mutation phenocopies *alg-1(0)*.

During adulthood, ALG-1 and specific miRNAs are involved in the aging process and regulate *C. elegans* lifespan. Loss of *alg-1*^{45,46} and miRNAs such as *lin-4*, miR-71, miR-228, miR-238 and miR-246⁴⁷⁻⁵¹ leads to a shortened lifespan. We found that, as reported for *alg-1(0)*⁴⁶, *alg-1(S642E)* mutant animals have an average lifespan that is significantly shorter than that of wild-type animals (Figure 1C). Moreover, upon entering adulthood, ALG-1 protein levels were shown to drastically decrease⁴⁶. We observed a similar decrease for wild-type ALG-1, ALG-1 S642A and ALG-1 S642E proteins after animals had reached adulthood (Figure 1C), suggesting that a decrease in ALG-1 expression levels in *alg-1(S642E)* mutants is not sufficient to explain the shorter lifespan (Figure 1C) and instead hinting at a defect in ALG-1 activity.

In contrast to *alg-1(0)*, the expression of the phospho-mimicking mutant caused defects in embryonic development (Figure 1D). Specifically, phospho-mimicking *alg-1(S642E)* adult animals laid eggs that remained unhatched, indicating a defective development leading to embryonic arrest. In animals completely depleted of *alg-1*, the activity of ALG-2 is sufficient to maintain the miRNA activity required for viability, but the simultaneous depletion of *alg-1* and *-2* leads to embryonic arrest¹⁹. In agreement with this, we were unable to isolate homozygous mutants of *alg-1(S642E)* and *alg-2(0)* but the double mutant *alg-1(S642A); alg-2(0)* were viable (Figure 1D). The embryonic lethality observed in *alg-1(S642E)* suggests that this mutation is more deleterious than the loss of *alg-1*. Concurrently, incomplete penetrance of this phenotype indicates that the miRNA pathway and ALG-2 retain at least partial function in the mutant animals. It also reveals that the defects in *alg-1(S642E)* cannot be explained by a decreased expression of ALG-1 alone, since embryonic lethality does not occur upon loss of *alg-1*.

The phosphorylation site serine 642 is located on the AGO MID domain, which is responsible for the 5' nucleotide recognition and binding of the miRNA^{52,53}. To determine whether the embryonic lethality could occur in animals in which ALG-1 is defective for miRNA binding, we produced a mutant strain, *alg-1(Y693E)*. The mutation of this conserved tyrosine to a glutamate located within the 5' nucleotide binding pocket of the AGO was shown to disrupt miRNA loading of the human AGO2 (Y529E)⁴⁰. As for the phospho-mimicking *alg-1(S642E)* mutants, *alg-1(Y693E)* animals also showed a noticeable number of unhatched eggs (Figure 1D). Taken together, these results show that phospho-mimicking *alg-1(S642E)* mutation leads to a loss of function of *alg-1* and impairs *C. elegans* development during embryogenesis as well as post-embryonically. Furthermore, dead embryos were observed in animals expressing a miRNA-binding mutant of *alg-1*, *alg-1(Y693E)* as well as in *alg-1(S642E)* mutants but not in *alg-1(0)*, which suggests that S642E and Y693E could affect ALG-1 function in a similar way.

Delayed larval development in phospho-mimicking ALG-1 S642E mutants

Since our results indicate that constitutive phospho-mimicking of ALG-1 (S642E) leads to a loss of function of the miRNA-specific AGO, we were interested to know whether this phosphorylation event could be important at any point during *C. elegans* development, where several processes are controlled by miRNAs⁵⁴. We noticed that *alg-1(S642E)* mutants reached adulthood a few hours after wild-type animals. To determine whether those delays were caused at a specific stage during development and help us understand the biological relevance of this phosphorylation site, we used a luminescence-based assay^{55,56} to quantify developmental tempo. This assay detects lack of food uptake in animals during lethargus (molt) through a drop in luminescence signal. Specifically, we cultured animals expressing luciferase from a single copy integrated transgene in the presence of the luciferase substrate D-luciferin. Luminescence emission requires the ingestion of luciferin, which only occurs outside molts, i.e., in intermolts. Hence, by tracking animals individually in the wells of a multiwell plate, we can identify molt entry through a sudden drop in luminescence signal, and molt exit through a steep increase in signal. We can thus quantify the duration of molts (time between drop and increase) and intermolts (between increase and drop). A larval stage is the sum of duration of molts and intermolts.

We found that for the phospho-mimicking *alg-1(S642E)* mutant animals, all four larval stages were lengthened due to an increase in the durations of all intermolts and molts except for molt 2 (Figure 2). Moreover, although *alg-1(S642A)* mutant animals appeared wild-type in our other assays, they displayed some alterations in developmental tempo. Thus, the durations of the first and second larval stages were increased relative to wild-type animals due to a lengthening of intermolts, most prominently the first intermolt (Figure 2A and 2B). Additionally, the durations of molts 2 and 3 were modestly increased and that of intermolt 4 decreased. We conclude that both mutations alter developmental timing with a stronger effect observed for *alg-1(S642E)*.

The ALG-1 S642E phospho-mimicking mutant does not affect its interaction with AIN-1 nor its ability to silence mRNAs

Protein phosphorylation can have a broad range of effects on its conformation, stability, localization or interacting partners. An important component of the miRISC is the scaffold protein GW182 that directly interacts with AGO to recruit deadenylation enzymes such as PAN2/3 or the CCR4/NOT complex that removes the poly(A) tail of the mRNA¹⁶. Co-immunoprecipitation experiments of ALG-1 and the GW182 protein AIN-1 showed that wild-type ALG-1, ALG-1 S642A and ALG-1 S642E mutants interacted comparably with AIN-1 (Figure 3A). This suggests that the phosphorylation status of serine 642 does not affect the interaction between AGO and GW182. To determine if the phosphorylation of serine 642 might affect the ability of ALG-1 to reduce protein synthesis once bound to mRNAs, we used a λ N/Box-B tethering reporter that enables gene silencing without the requirement for miRNA:mRNA interaction^{41,57}. Endogenously tagged λ N::ALG-1 variants were co-expressed with a single copy integrated transgene of GFP with Box-B sequences in the 3' UTR. Expressing a λ N tagged ALG-1 S642A or ALG-1 S642E was as efficient as the λ N tagged wild-type ALG-1 to silence the expression of GFP (Figure 3B). Taken together, these results indicate that the phosphorylation status of serine 642 does not affect the silencing efficiency of ALG-1 artificially bound to the 3' UTR of a target mRNA.

The ALG-1 S642E mutation affects the abundance of both guide and passenger miRNA strands

AGOs are at the core of the miRISC and, as the carrier of miRNAs, they play a major role in promoting their maturation from the pre-miRNA to their mature form^{10,58-60} and protect the mature miRNA from degradation by exonucleases. Hence, variations in the ability of AGO to bind miRNAs is expected to have repercussions on the miRNA levels. To assess whether serine 642 phosphorylation could have such an effect, we measured the abundance of miRNAs by high-throughput sequencing. We found that, while miRNA levels in *alg-1(S642A)* mutants were overall indistinguishable from wild-type animals (Figure 4A), several miRNAs were significantly decreased in adult *alg-1(S642E)* mutant animals (Figure 4B and 4D) and throughout the larval development (Figure S2 and S3). *alg-1(S642E)* mutants showed alae formation defects and vulva rupturing (Figure 1A and 1B) which are typically caused by misregulation of the let-7 miRNA family. While miR-48-5p and miR-84-5p were expressed at similar levels compared to wild type at various time points, the expression of let-7-5p was delayed by a few hours and miR-241-5p was decreased at all time points (Data S1). These data indicate that misregulation of the let-7 miRNA family during development could indeed contribute to the larval phenotypes in *alg-1(S642E)* (Figure 1A and 1B). We performed miRNA quantification in embryo by RT-qPCR for miR-35-42 and miR-51-56 miRNA families because these two miRNA families are required for embryogenesis⁶¹⁻⁶³. We observed a modest but significant decrease for miR-35-42 miRNA family that occurred in both *alg-1(S642A)* and *alg-1(S642E)*, while miR-51-56 miRNA family was not affected (Figure S4A), suggesting a potential contribution of miR-35-42 miRNA family in the embryonic phenotypes observed in *alg-1(S642E)* mutants (Figure 1D).

Interestingly, this sequencing data showed that several passenger strands (miR*) were more abundant in the *alg-1(S642E)* mutants than those measured in wild-type animals (Figure 4B

right panel). Although many passenger strands were more abundant in *alg-1(S642E)* mutant animals, their reads never exceeded those of the guide strands. Specifically, passenger strands that showed a significant increase ($p < 0.05$) in *alg-1(S642E)* compared to wild-type animals are miR-51-3p (10 fold), miR-56-5p (6 fold), miR-58-5p (7 fold), miR-64-3p (6 fold), miR-71-3p (12 fold), miR-238-5p (32 fold), miR-244-3p (9 fold), and miR-1822-5p (4 fold). We confirmed the increase of miR-51-3p by Northern blot (Figure 4C) and miR-71-3p and miR-238-5p by RT-qPCR (Figure 4D). Taken together, these results show that phosphorylation of ALG-1 serine 642 affects the abundance of both the guide and passenger strands during *C. elegans* development.

Phosphorylation of ALG-1 serine 642 affects miRNA binding

Alteration of miRNA levels can be attributed to different mechanisms mediated by AGO. First, the processing of some precursor miRNA into mature miRNA is decreased in the absence of ALG-1^{18,26}, which did not occur for miR-51, as the levels of the precursor form was not affected in *alg-1(0)* nor *alg-1(S642E)* (Figure 4C). Second, AGO stabilizes miRNAs through binding and thus protects them from nuclease-mediated degradation, a mechanism that can be regulated in cells by exposing the 3' end of miRNA to modifications or by degradation of AGO by the ubiquitin-proteasome⁶⁴⁻⁶⁷. To investigate if ALG-1 phosphorylation at serine 642 could prevent miRNA binding and thus lead to the differences in miRNA levels observed in the phospho-mimicking *alg-1(S642E)* mutant, we immunopurified wild-type ALG-1, ALG-1 S642A and ALG-1 S642E and quantified the associated miRNAs with high-throughput sequencing. We observed a global decrease in miRNA population bound to the phospho-mimicking ALG-1 S642E compared to wild type (Figure 5A). In contrast, the abundance of miRNAs associated with the non-phosphorylatable ALG-1 S642A mutant was indistinguishable from wild-type ALG-1 (Figure 5A). The decrease in miRNA association of ALG-1 S642E was also observed when we pulled down miR-35 miRISC (Figure 5B). These results reveal that phospho-mimicking ALG-1 S642E impairs the function of ALG-1 by decreasing its ability to bind miRNAs.

Surprisingly, although passenger strands accumulated in the total RNA of *alg-1(S642E)* mutant animals (Figure 4B-4D), this did not coincide with an increased passenger strand binding to ALG-1 S642E (Figure 5C). This suggests that the affected passenger strands accumulate without binding to ALG-1. Indeed, most matching guide strands did not exhibit a substantial decrease in levels (Figure S4B), suggesting that the *alg-1(S642E)* mutant phenotypes do not generally derive from a switch in miRNA strand loading onto ALG-1. Instead, these data may be parsimoniously explained by a defect in loading of the miRNA guide:passenger strand duplex onto ALG-1. Duplexes may thus accumulate unbound to ALG-1 in the cytoplasm, and binding to the guide strand may render the passenger strand refractory to single-strand nucleases that would normally degrade evicted passenger strands after loading of the guide strands into ALG-1. Concurrently, this would diminish the amounts of functional, ALG-1-loaded guide strands and thus explain why miRNA activity is decreased despite little changes in overall cellular miRNA guide strand levels.

The protein kinase A phosphorylates serine 642 *in vitro* and genetically interacts with *alg-1*

To determine which pathway(s) can regulate ALG-1 through phosphorylation of serine 642 residue, we first used Netphos 3.1⁶⁸ to predict kinases that can use this specific amino acid as substrate. The protein kinase A (PKA) was the only kinase with a positive score (0.62). PKA is a 3',5'-cyclic adenosine monophosphate (cAMP)-dependent serine/threonine kinase complex composed of a catalytic and a regulatory subunit known as KIN-1 and KIN-2 in *C. elegans*, respectively⁶⁹⁻⁷¹. In the absence of cAMP, PKA forms an inactive tetramer (holoenzyme) of two regulatory and two catalytic subunits. Upon stimulation, adenylyl cyclase produces cAMP from ATP. The regulatory subunit binds to the cAMP and triggers a conformational change that reduces the affinity for the catalytic subunit and allows it to phosphorylate its substrates (Figure 6A). To determine whether ALG-1 serine 642 can be phosphorylated by PKA, we performed an *in vitro* kinase assay using different peptides of ALG-1 spanning 18 amino acids and incubated them with recombinant PKA (Figure 6B-C). Incorporation of radioactive phosphate was reproducibly detected, and the *in vitro* phosphorylation was specific to serine 642 as the signal was lost when we used a peptide in which the serine had been replaced by an alanine (Figure 6B-C). The consensus sequence along with the *in vitro* phosphorylation of ALG-1 peptides suggest that PKA could target ALG-1 to regulate its activity.

To investigate whether PKA contributes to the regulation of ALG-1 *in vivo*, we first determined whether PKA genetically interacts with *alg-1* and the miRNA pathway by depleting the regulatory subunit, *kin-2*, with RNAi. A decrease in KIN-2 levels will stimulate KIN-1 activity and could thus cause similar phenotypes as those observed in *alg-1(S642E)* if serine 642 is a *bona fide* substrate of PKA. We observed that, as for *alg-1(S642E)* mutants (Figure 1A), *kin-2* RNAi treated animals showed alae defects. More importantly, those defects were suppressed in the non-phosphorylatable *alg-1(S642A)* mutant exposed to *kin-2* RNAi (Figure 6D). These data indicate that the alae defects occurring upon the *kin-2* knockdown in animals require the phospho-acceptor residue serine 642, suggesting that PKA might regulate ALG-1 phosphorylation *in vivo*. Since *kin-2* RNAi produced severe developmental defects and early adult lethality, we decided to use a hypomorphic *kin-2(ce179)* allele to gain further evidence of the involvement of PKA in this process. This *kin-2* allele contains a point mutation on a conserved residue (R92C) in the auto-inhibitory domain that interacts with the catalytic subunit leading to an increased PKA activity^{72,73}. *kin-2(R92C)* larvae mutant animals are viable but take a longer time to reach adulthood, produce fewer progeny than wild-type animals and have an egg laying phenotype (Egl)⁷³. To strengthen the evidence that PKA antagonizes *alg-1*, we tested whether the depletion of *alg-2* in the *kin-2* mutant would cause a synthetic lethality phenotype as it is the case for the loss of both *alg-1* and *alg-2*¹⁹. To do so, we generated a double mutant with *kin-2(R92C)* and a knockout strain of *alg-2 (alg-2(ok304))*. We observed that the loss of *alg-2* in the hyperactive PKA strain led to adult lethality caused by egg laying defects (Bag of worms phenotype) along with a few larvally arrested worms. These phenotypes were suppressed in a triple mutant including the non-phosphorylatable *alg-1(S642A)* mutant (Figure 6E). This genetic assessment shows that activated PKA antagonizes ALG-1 *in vivo*, in a serine 642 dependent manner. The *in vitro* phosphorylation assays strongly suggests that PKA could regulate ALG-1 function through its phosphorylation on serine 642. Overall,

our results demonstrate a regulatory mechanism for AGO protein in *C. elegans*, in which ALG-1 phosphorylation on serine 642 reduces its binding to miRNAs and impairs the formation of functional miRISC, and present evidence that the PKA signalling pathway is likely responsible for this phosphorylation *in vivo*.

DISCUSSION

In this study, we report the phosphorylation of a specific serine residue on the MID domain of the *C. elegans* AGO ALG-1 that modulates its ability to bind miRNAs. Our *in vivo* analysis of the phosphorylation mutants of ALG-1 serine 642 reveals that the constitutive phosphorylation of this residue (mimicked by S642E) produces loss-of-function phenotypes during embryonic and larval development. Since embryonic lethality from the loss of miRNA function arises from the lack of both AGOs ALG-1 and ALG-2 activity in embryos, this phenotype in *alg-1(S642E)* and *alg-1(Y693E)* mutants suggests that miRNA-binding deficient ALG-1 would interfere with ALG-2 function by reducing the availability of important interactors for miRNA maturation and/or gene silencing. The evidence for such misregulation is the interaction between ALG-1 S642E and the GW182 protein AIN-1 (Figure 3A). We have previously reported that the interaction between AGO and GW182 is not strictly required for embryonic viability⁵⁷, suggesting the possibility that other factors at play produce this phenotype. Therefore, we looked at the interaction between ALG-1 S642E and DCR-1 that cleaves the precursor miRNAs to produce mature miRNA duplexes. ALG-1 S642E maintained its interaction with DCR-1 in adults (Figure S5B) and embryos (Figure S5C) despite that ALG-1 S642E mutant binds miRNA less efficiently. Thus, we speculate that, in addition to the reduced miRNAs binding (Figure 5), ALG-1 S642E mutants could impair the ALG-2 function through its association with DCR-1 and the RISC loading complex.

The *C. elegans* ALG-1 serine 642 was found to be phosphorylated *in vivo* (Figure S1A) which is a conserved residue on all four human AGOs (Figure S6A). Since this serine is conserved on the *C. elegans* ALG-2 (Figure S6A) and located in the vicinity of a basic amino acid (Arginine (R)) at position -2, which is typically found in PKA substrates, it will be interesting to determine whether ALG-2 can be phosphorylated. Furthermore, differences in the phosphorylation statuses between ALG-1 and ALG-2 during development could potentially explain the previously reported preferential loading of specific miRNAs^{19,20}. The abovementioned key residues are not found in ALG-5, another *C. elegans* AGO capable of binding to a specific subset of miRNAs in the germline (Figure S6A). Therefore, it is difficult to speculate if a specific post-translational modification on ALG-5 could share a similar function. Despite the sequence conservation around the residue corresponding the ALG-1 serine 642 on human AGOs (Figure S6A), we could not detect phosphorylation on the human AGO1-4 purified from cell cultures. It is possible that the phosphorylation on human AGOs only occurs in specific cell types or that the differences in their structural features prevent this phosphorylation. When we looked at the previously determined structures of the guide- and guide-target duplex-bound AGO1-4, most of them occludes the hydroxyl group on the side chain of the corresponding serine (Table S1)^{25,27,65,74-79}. In contrast, the hydroxyl group on the side chain of serine 642 is solvent-exposed in the model of apo-ALG-1 (RNA-free form of ALG-1) available from the AlphaFold Protein Structure

Database EMBL server (<https://alphafold.ebi.ac.uk>) (Figure S6B-C). These observations suggest that the phosphorylation of this serine could either be *C. elegans* specific or that residue can only be phosphorylated before the miRISC formation. We performed experiments in HEK 293T to determine whether mutations of AGO2 serine 478 (the serine corresponding to ALG-1 serine 642) impair miRNA function, and observed that although miRNA levels were not affected upon overexpression of Flag/HA AGO2 S478E (Figure S6D), both Flag/HA AGO2 S478E and the miRNA binding mutant Flag/HA AGO2 Y529E decreased binding to mRNAs (Figure S6E). Although the conservation of this phosphorylation event in human cells is not yet clear or under which biological conditions it would occur, these results indicate that serine 478 is an important residue for AGO2 function. The addition of a negative charge at this position, by either phosphorylation or a somatic mutation, would impair the miRNA function and impact human cell homeostasis.

As opposed to the human AGO2 phosphorylation site Y529 forming the miRNA binding pocket⁴⁰, ALG-1 serine 642 is located on a helix at the surface of the MID domain (Figure S6C). While both phosphorylation impair binding to miRNA, the modification of Y529 is thought to prevent miRNA binding by sterically hindering the 5' phosphate of the miRNA or by the proximity of the negative charges carried by both the phospho-tyrosine and the miRNA 5' phosphate. Conversely, ALG-1 serine 642 is located on the surface of the MID domain and thus does not seem to interact with the miRNA 5' end or its sugar-phosphate backbone. Therefore, this phospho-serine would decrease the binding to miRNAs by a different mechanism, such as locking the AGO in an open conformation, and preventing the transition toward the closed conformation after miRNA binding. Although the bulk of miRNAs are strongly decreased in ALG-1 S642E IP compared to wild-type ALG-1, the binding to specific miRNAs remains reproducibly efficient (Figure 5C and S5A), which could deny the possibility that the phosphomimetic mutant ALG-1 S642E remains in open conformation. We speculate that there could be a sequence bias or that the stability of the miRNA duplex end could allow specific miRNAs to be sorted into ALG-1 S642E as efficiently as for the wild-type protein and form of a functional miRISC.

Mutations in conserved residues of ALG-1 MID domain that result in accumulation of passenger strands, like in *alg-1(S642E)*, have been reported in *C. elegans*^{80,81}. Genetically, the antimorphic mutant allele *alg-1(ma202)* contains an amino acid substitution G553R and has phenotypes that are more penetrant than for *alg-1(0)* mutant animals. In comparison, *alg-1(S642E)* mutants have less severe phenotypes compared to *alg-1(0)* during larval development (Figure 1A and 1B) but more severe defects during embryonic development (Figure 1D). The difference in phenotypes and their severity indicate that *alg-1(S642E)* and *alg-1(G553R)* have distinct molecular effects. As observed for ALG-1 S642E (Figure S5B-C), ALG-1 G553R proteins associate with DCR-1 but unlike ALG-1 S642E, ALG-1 G553R poorly associates with the miRISC effector AIN-1, suggesting that the latter sequester miRNAs in ineffective complexes. ALG-1 S642E associate with AIN-1 (Figure 3A) and silence GFP protein expression as effectively as wild-type ALG-1 when tethered to the 3' UTR of the mRNA (Figure 3B), suggesting that ALG-1 S642E can form an effective miRISC despite the decrease in miRNA binding. Both mutants show a strong increase in passenger strands but apparently for different reasons. In *alg-1(G553R)* mutants, passenger strands are inappropriately loaded in ALG-1, which in turn, protects them from degradation.

In contrast, ALG-1 S642E does not selectively bind passenger strands when compared to wild-type ALG-1 (Figure 5C). This indicates that passenger strands in *alg-1(S642E)* might not be dissociated from the guide strands and accumulate as duplexes which could also explain the modest decrease for many guide miRNAs (Figure 4A, S4A and S4B) despite their inefficient binding to ALG-1 S642E (Figure 5A-C).

In the *alg-1(S642E)* mutant animals, while we observed a robust decrease in miRNAs associated to ALG-1, we also noticed a decrease in ALG-1 levels at L4 stage and in adults (Figure 1C and S1D). Although a decrease in ALG-1 protein levels could contribute to the phenotypes observed in *alg-1(S642E)* mutants, the stronger phenotypes compared to *alg-1(0)* animals (Figure 1D) shows that this decrease in ALG-1 S642E levels is not sufficient to explain them. Various reports show that apo AGOs are selectively degraded by either the proteasome or through the lysosome⁸²⁻⁸⁵. Blocking the proteasome using MG132 proteasome inhibitor was not sufficient to restore ALG-1 S642E levels (Figure S1D). It will be interesting to test whether ALG-1 S642E mutant is sorted into autophagy as recently found in fly Ago1 miRNA-binding mutants^{85,86}.

PKA is implicated in several biological processes, including lipid metabolism, rhythmic behavior, locomotion, immunity and stress response⁸⁷⁻⁹². Beside its important role to regulate the transcriptional activation of target genes through the phosphorylation of CREB family proteins⁹³, PKA was shown to regulate mRNA translation⁹⁴⁻⁹⁶ and mRNA decay⁹⁷. The regulation of the AGO phosphorylation by the cAMP signalling provides an additional mechanism for post-transcriptional regulation of gene expression. Our phenotypical analyses in the non-phosphorylatable *alg-1(S642A)* mutants indicates that ALG-1 serine 642 phosphorylation is not required for the synthesis of the alae, the formation of the vulva and during embryogenesis (Figure 1A-B and 1D). Therefore, we do not foresee a sustained regulation of ALG-1 by PKA in those tissues throughout development. In the context of PKA signalling, the activity of the catalytic subunit KIN-1 is under tight regulation and inhibited by the regulatory subunit KIN-2 in cells until its activation. In this signalling pathway and upstream of the second messenger cAMP that activates KIN-1 by releasing KIN-2, are found the G-protein coupled receptors (GPCRs). There are approximately 1,300 predicted or curated genes encoding GPCRs in *C. elegans*⁹⁸, that respond to different extracellular stimuli and ligands. The model that we envision for the role of ALG-1 inactivation by PKA is as follows: upon activation of PKA, several genes are upregulated or downregulated by transcriptional and post transcriptional means. Among the transcripts that are positively regulated by PKA, some are also putative miRISC targets which hinders their expression. The phosphorylation of ALG-1 serine 642 by PKA decreases ALG-1 binding to miRNA and thereby, promotes the expression of PKA induced genes that contain miRNA binding sites. In *C. elegans*, PKA have been shown to upregulate a specific set of antimicrobial genes in the neurons, in response to *Salmonella enterica* infection⁹¹. It will be an interesting way to test our model by exposing *alg-1(S642A)* mutants to *S. enterica* infection to determine if 1) ALG-1 is involved, through its modification by PKA, in innate immunity response and 2) whether serine 642 phosphorylation promotes the expression of the same set of genes as PKA, upon PKA activation in the neurons.

Altogether our study indicates miRNA-mediated gene regulation pathway interacts with the cAMP signalling pathway. Specifically, phosphorylation of ALG-1 on serine 642 by PKA decreases AGO ability to bind miRNAs. As only specific cells might undergo activation of PKA at a given time during normal growth conditions and might be restricted by compartmentalization in others, the identification of the processes that incurs the miRISC inactivation will be crucial to understand its biological function. For this purpose, it will be important in the future to survey different conditions and environmental stresses if we want to uncover how this important gene regulation pathway is controlled.

Limitations of the study

There are potential caveats in our approach that needs to be considered when interpreting the data. Phospho-mimicking ALG-1 mutations were used to characterize the effect of serine 642 phosphorylation. While those variants are broadly used to study protein phosphorylation, they do not always fully recapitulate the phospho-substrate (for example^{99,100}), hence the data reported here only describes the molecular and biological effect of ALG-1 phospho-mimicking substitution. The contribution of serine 642 phosphorylation *in vivo* could differ from what is observed with ALG-1 S642E mutant.

We showed that *kin-2* interacts genetically with *alg-1*. The genetic suppression of *kin-2* phenotypes by *alg-1(S642A)* indicates that ALG-1 phosphorylation ablation counteracts the effects of KIN-1 activation. While this could mean that *alg-1* and *kin-1/kin-2* are part of the same pathway, this data alone is not sufficient to conclude that ALG-1 is a direct substrate of KIN-1. KIN-1 activation could affect different kinases and phosphatases that regulate ALG-1 and hence, stimulate serine 642 phosphorylation indirectly. *In vitro* phosphorylation of serine 642 were conducted with recombinant PKA enzyme and ALG-1 peptides. This data provides evidence that PKA can recognize and phosphorylate serine 642 site, but does not recapitulate the context of protein folding, structure and protein-protein interactions *in vivo*.

This study focuses on ALG-1 serine 642 phosphorylation; the phosphorylation of ALG-2 and its biological relevance remains to be investigated. Our phenotypical analyses of the non-phosphorylatable *alg-1(S642A)* mutant animals showed developmental delays during the first two larval stages, indicating that serine 642 phosphorylation positively regulates early larval development. Quantitative mass spectrometry analyses of ALG-1 phosphorylation at different time points during development will be required to determine whether there is a prominent phosphorylation at those stages.

Last, this study did not address the localization of ALG-1 in cells. The mislocalization of ALG-1 S642E could affect the loading process and the miRISC turnover dynamic. Similarly, *in vitro* analysis of phospho-mimicking ALG-1 S642E miRNA binding and duplex unwinding will be a matter of future study to address the biochemical effect of serine 642 phosphorylation on AGO.

STAR Methods

RESOURCE AVAILABILITY

Lead contact—Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Martin J. Simard (martin.simard@crchudequebec.ulaval.ca).

Materials availability—All unique and stable reagents and strains generated in this study are available from the lead contact without restriction.

Data and Code availability—Raw and processed small RNA-seq datasets have been deposited at NCBI's Gene Expression Omnibus (GEO) repository and are publicly available as of the date of publication. Accession numbers are listed in the key resources table.

This paper does not report original code.

Additional information required to reanalyze the data in this study is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

***C. elegans* model and methods**—All *C. elegans* strains were cultured on nematode growth medium (NGM) agar, fed with *E. coli* OP50 and handled using standard methods¹⁰¹ unless indicated otherwise. Hermaphrodite animals were used for all *C. elegans* experiments. Developmentally staged embryos, larvae and young adult animals were used. The animal stage used for each experiment can be found in the respective figure's legend. The transgenic strains were obtained by micro-injection in young adults to produce progeny carrying extrachromosomal non-integrated transgene arrays¹⁰². The plasmid *alg-1p::lambdaN::mCherry::alg-1g::alg-1 3'UTR* plasmid (MSP0186) was generated in⁵⁷. MSP0186 *alg-1* serine 642 codon was mutated into alanine or glutamate with the oligonucleotides listed in Table S2, using Q5 Site-Directed Mutagenesis Kit (NEB). Genome editing of *C. elegans* with CRISPR-Cas9 methods was carried out by micro-injection in young adult animals with reconstituted Cas9 RNP mix [Cas9 protein (2.5 µg/µL), tracrRNA (1 µg/µL), CRISPR guide RNA (crRNA) (0.4 µg/µL) and repair templates with short homology arms (ssODN; 1.625µM)]¹⁰³ (Table S2). F1 heterozygotes and F2 homozygotes were determined by PCR genotyping and Sanger sequencing. Missense mutations of *alg-1* loci were carried out in a wild-type N2 (Bristol) strain. Missense mutations of *alg-1* were obtained additionally in a strain where *alg-1* is endogenously tagged in N-terminus with λN in a genetic background containing a single-copy insertion of GFP::*cog-1-boxb* reporter^{41,57}. *kin-2(R92C)* was produced in *alg-2(ok304)* and in the double mutant *alg-1(ok304); alg-1(S642A)* background using CRISPR-Cas9, as described above. All strains that were used for this study are listed in the key resources table and the oligonucleotides used for genome editing can be found in Table S2.

Cultivation of HEK293 T cells—HEK 293T cells were cultivated under standard conditions (37 °C, 5 % CO₂) using Dulbecco's modified Eagle Medium (DMEM, Gibco) supplemented with 10 % FBS (Sigma-Aldrich) and 1% penicillin-streptomycin (Sigma-

Aldrich). For cultivation, cells were passaged to a new dish every two to three days. Authentication was not performed. HEK 293T cells originate from a female embryo.

METHOD DETAILS

RNA interference—Knockdown of *alg-2* and *kin-2* were carried by feeding¹⁰⁴. cDNA fragments of *alg-2* and *kin-2* were cloned into L4440 plasmid and transformed in the inducible IPTG HT115 (DE3) bacterial strain. L1 staged worms were grown at 20°C on IPTG Agar plates seeded with the respective bacterial strains or with bacteria transformed with L4440 control plasmid.

Lifespan analyses—All strains were cultured under standard conditions and synchronized by alkaline hypochlorite solution treatment. Lifespan assays⁴⁶ were conducted at 20°C. Embryos were plated on NGM plates containing OP50. At the L4 stage, 20 animals were transferred to one plate, and 5 plates were counted for each strain. First day after the L4 stage was noted as day 1. Adult worms were transferred every 2 days during active reproduction and scored for viability. Animals were scored as dead when they stopped responding to gentle prodding with a platinum wire pick. Dead animals were removed from the plates. Animals that died by internal hatching, vulval bursting, or crawling on the side of the plates were censored from the lifespan analysis. *P*-values were calculated using the Mantel-Cox log-rank test.

Preparation of protein extracts, immunoprecipitation and Western Blotting analysis—Synchronized worm populations were obtained by alkaline hypochlorite solution treatment and plated onto NGM agar plates seeded with *Escherichia coli* OP50 bacteria. Animals were cultured at 20°C until adult stage then washed in M9 buffer, resuspended in ice-cold lysis buffer solution (100 mM potassium acetate, 30 mM Hepes-KOH pH 7, 2 mM magnesium acetate, 1 mM DTT, 1.5% [v/v] Triton X-100, 1 tablet/10 ml Complete Mini Protease Inhibitor without EDTA (Roche)) and lysed using a Dounce homogenizer. For immunoprecipitation, 12.5 μ L of Dynabeads protein G (Thermo Fisher Scientific) were washed three times with lysis buffer and then incubated with ALG-1 antibody in 200 μ L PBST for 1 hour with rotation. Beads were washed three times with lysis buffer and incubated with 1mg of worm extract (500 μ L), for 3 hours at 4°C with rotation. Beads were resuspended in 20 μ L 2X SDS loading buffer and eluted by heating at 95°C for 10 min before loading on gel for SDS-PAGE. For ALG-1 Western blotting, primary rabbit polyclonal ALG-1 antibodies were used at 1:1000 dilution in PBST supplemented with 1% [v/v] bovine serum albumin, AIN-1 and DCR-1 antibodies¹⁰⁵ were used at 1:5000 in PBST; 5% [w/v] dried milk and beta-ACTIN (abcam, ab49900) was diluted 1:10000 in PBST 5% [w/v] dried milk with overnight incubation at 4°C. For ALG-1 expression at L4 and adult stage in Figure 1C, exactly 75 worms were picked and directly boiled in SDS Sample loading buffer (1 mM Tris-HCl [pH 6.8], 2% [w/v] SDS, 100mM DDT and 10% [v/v] glycerol) for western blot analysis.

Assessment of ALG-1 expression and proteasomal degradation—Hand-picked animals were harvested at the young adult stage. The worms were treated by rotating them in suspension for two hours with vehicle only (DMSO) or with 50 μ M of MG132

(Sigma-Aldrich, 474790) in M9. Harvested animals were collected and washed in M9 before being lysed in SDS loading buffer (1 mM Tris-HCl [pH 6.8], 2% [w/v] SDS, 100mM DDT and 10% [v/v] glycerol). The homogenized extract was clarified by centrifugation at 17,000× g for 5 min at 4°C. To detect ALG-1 or ACTIN, the total protein extract was boiled for 10 minutes in SDS loading buffer and proteins were resolved on 8% acrylamide gel and transferred to Protran Premium NC membranes (GE Healthcare). Membranes were incubated overnight at 4°C with either antibody: (i) Rabbit polyclonal against ALG-1 diluted 1:1,000 or (ii) Mouse monoclonal against beta-ACTIN (Abcam, ab49900) diluted 1:20,000; Ubiquitin (Santa Cruz, sc-8017) diluted 1:400. Antibodies were diluted in PBST-1% bovine serum albumin solution (137mM NaCl, 10 mM Phosphate, 2.7mM KCl [pH 7.4], 0.05% [v/v] Tween-20 and 1% [w/v] bovine serum albumin). The membrane was incubated for 1 hour at room temperature with HRP-conjugated secondary antibody in PBST and then revealed using Western Lightening ECL Kit (Perkin Elmer) and visualized using Chemidoc imaging system (BioRad).

Luciferase assays—To perform Luciferase assays⁵⁶, *C. elegans* expressing the *xeSi296* transgene [*eft-3p::luc::gfp::unc-54 3'UTR, unc-119(+)*] II were grown until they became gravid adults. The embryos were extracted using an alkaline hypochlorite solution treatment and single eggs were transferred by pipetting into a well of a flat-bottom, white 384-well plate (Berthold Technologies, 32505). The embryos hatched and developed in 90 µl S-Basal medium containing food (*E. coli* OP50 at OD₆₀₀ = 0.9) and substrate for luciferase (100 µM Firefly D-Luciferin) (p.j.k., 102111). Plates were sealed with a breathable sealing membrane (Breathe Easier, Diversified Biotech, BERM-2000). Luminescence signal was measured using a Luminometer (Berthold Technologies, Centro XS3 LB 960) for 72 hours of development at 20°C in an incubator for 0.5 seconds every 10 minutes in a temperature-controlled incubator. Analysis of luminescence data was done in MATLAB using an automated algorithm to detect the hatch and the molts⁵⁶.

Time-course small RNA sequencing and processing—N2 and *alg-1* mutant animals were grown until gravid adults. Synchronized L1s were prepared by alkaline hypochlorite solution treatment and hatching them in absence of food in M9 buffer for 15h. The worms were plated on 2% NGM agar plates with *Escherichia coli* OP50 bacteria and placed at 25°C. From 18h to 30h of development, worms were collected hourly by washing them off the plates with M9. Worms were subjected to five cycles of freeze thawing in liquid nitrogen and a 42°C heat block, respectively, in TRI Reagent (LucernaChem, TR-118). After the lysis of worms, RNA isolation was performed with phenol-chloroform extraction (adapted from¹⁰⁶). Subsequently RNA was treated with DNase (Life Technologies) and used for preparing small-RNA libraries.

For the time course experiments, the libraries were prepared using a QIAseq miRNA Library Kit (Qiagen) according to manufacturer's protocol. This was followed by sequencing using the HiSeq 50 Cycle Single end reads protocol on HiSeq 2500. 3' adapters (AACTGTAGGCACCATCAAT) were trimmed with cutadapt¹⁰⁷ with the following options (--error-rate 0.1, --minimum-length 15, --overlap 3). Reads were mapped to the genome with bowtie¹⁰⁸ (version 1.2.2) with the following options (-v 1, -m 100, --best,

--strata, --fr). Alignments were sorted and indexed with samtools¹⁰⁹ (version 1.9). Reads mapping to rRNA, rRNA_pseudogene, tRNA, tRNA_pseudogene or from the mitochondrial chromosome were excluded (based on the Wormbase 4 WS270 annotation¹¹⁰). The mature miRNAs from miRBase¹¹¹ (version 22) and reads were counted with HTSeq¹¹² (version 0.11.2) with the following options (--stranded yes, --type miRNA, --idattr Name, --mode union).

RNA isolation of adult animals, Northern blot and RT-qPCR—Total RNA was purified by resuspending worm pellet in TRI Reagent (Sigma) and lysed by flash-freezing in liquid nitrogen three times. 30 micrograms of total RNAs were used for northern blot. Samples were mixed with an equal volume of 2x Loading Dye (8 M urea, 25 mM EDTA, 0.025% [w/v] xylene cyanol (XC), 0.025% [w/v] bromophenol blue (BB)) and heated at 80°C. 15% Urea Gel PAGE (Sequagel solutions) was pre-ran for 20 minutes before loading the samples. The gel was transferred onto Amersham Hybond-ECL nitrocellulose membrane (GE Healthcare). The RNA was cross-linked to the membrane with an EDC solution [0.373g (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide and 1x methylimidazole (127.5 mM 1-methylimidazole-HCl [pH 8]) at 60°C for 1 hour. The membrane was then washed with water several times and baked at 80°C for 10 minutes. The membrane was pre-hybridized in a hybridization bottle with 50 mL (5X SSC, 20 mM Na₂HPO₄ pH 7.2, 7% [w/v] SDS, 2X Denhardt's Solution and 1 mg of freshly denatured sheared salmon sperm DNA) at 50°C for 2 hours with rotation. Probes were radiolabelled with IDT StarFire reagents (discontinued), heated at 85°C for 5 minutes, directly added to the pre-hybridization solution, along with the membrane, and incubated overnight at 50°C with rotation. The membrane was washed three times in non-stringent wash solution (3X SSC, 5% [w/v] SDS) and once with stringent wash solution (1X SSC, 1% [w/v] SDS), at 50°C for 20 minutes with rotation. Phosphorimager screen was exposed with the membrane (overnight for miR-51 probes and 1 hour for tRNA glycine probe) and revealed by autoradiography. Membranes were stripped by adding 100 mL of boiled 0.1% [w/v] SDS solution and incubating at 50°C for 20 minutes with rotation.

RT-qPCR were performed with TaqMan miRNA Assay reagents (Life Technologies). CT values were obtained using snoRNA sn2841 as the endogenous control. To quantify the level of miRNA bound to ALG-1, 1 mg of total protein extract was used to immunoprecipitate ALG-1. 10% of the beads was suspended in 2x Laemmli denaturing buffer, heated at 95°C and loaded on 8 % SDS-PAGE to assess the efficiency of the immunoprecipitation by western blotting. 90 % of the remaining beads were suspended in 2X PK buffer (100 mM Tris-Cl [pH 7.5], 200 mM NaCl, 1% [w/v] SDS) and digested with proteinase K (20µg) at 50°C for 20 minutes. RNA was extracted from the solution using TriReagent (Sigma). Samples were spiked-in and normalized with synthetic human miR-20a (50fmol).

Small RNA cloning, sequencing and analysis of adult worms—Recombinant enzymes and oligonucleotides used for small RNA cloning were synthesized and provided by Dr. Weifeng Gu Laboratory^{113,114}. 1µg of total RNA or RNA purified from ALG-1 IP (1mg IP) was ligated in 3' with a 5' adenylated DNA oligonucleotide (AppAGATCGGAAGAGCACACGTCTGAACTCCAGTCA/3ddC/) and triphosphorylated small RNAs were dephosphorylated with recombinant *C. elegans* PIR-1 in a 10 µL reaction

[50 mM Tris (pH 7.5), 10 mM DTT, and 10 mM MgCl₂, PEG-8000 25% [v/v], 0.25 μM oligonucleotide, 0.25 μM truncated T4 RNA ligase 2, 0.25 μM PIR-1] for 2 hours at room temperature. The reaction was heat inactivated for 10 minutes at 65°C and then annealed in 3' with 5 μM oligonucleotide GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT starting at 65°C, decreasing at a rate of 0.1°C/second to 20°C over 5 minutes.

5' ligation was performed by adding 9.5 μL of ligation reaction [0.5 mM ATP, 0.125 μM T4 RNA ligase 1, and 0.2 μM RNA oligonucleotide (rArCrArCrUrUrUrUrCrCrCrUrArCrArCrGrArCrGrCrUrCrUrUrCrCrGrArUrCrU)] to the above reaction samples and incubated at room temperature for 2 hours. Reverse transcription was performed by adding 4.125 μL of [0.5 mM dNTP, 25 mM Tris, pH 8.8, 75 mM KCl, 5mM DTT and 0.125 μM Superscript II] to the reaction, incubated at 42°C for 30 minutes and heat inactivated at 85°C for 5 minutes.

PCR amplifications were carried out in a 50 μL PCR reaction of [1× PFU buffer (20mM Tris-HCl (pH 8.8), 10mM KCl, 10mM (NH₄)₂SO₄, 2mM MgSO₄, 0.1% [v/v] TritonX-100, 0.1 mg/ml BSA), 15 mM tetramethylammonium chloride, 0.1 mM dNTPs, 0.1 μM 5' and 3' oligonucleotides, 5 μL reverse transcribed samples, and 1× PFU polymerase]. 5' primers (AATGATACGGCGACCACCGAGATCTACACTCTTCCCTACACGA) and the 3' primers containing index (CAAGCAGAAGACGGCATAACGAGAT-index-GTGACTGGAGTTCAGACGTGT) were used. The PCR was first amplified for 5 cycles (94°C 20s; 53°C 20s; 68°C 30s) and then amplified for 11 cycles (94°C 20s; 68°C 40s). Additional 0.6 μM 5' and 3' primers were added to the mixture and the PCR was amplified for 2 more cycles (94°C 20s; 68°C 40s).

PCR products were compared on 8% native PAGE gel, pooled according to the measured ratio, purified by phenol-chloroform, precipitated and gel-purified.

Hiseq 4000 SR50 sequencing reads were mapped to the genome and cDNA using custom PERL (5.10.1) scripts and Bowtie 0.12.7¹⁰⁸. Databases used include *C. elegans* genome (WormBase release WS215), Repbase 15.10¹¹⁵, and miRBase 16¹¹⁶. The Generic Genome Browser¹¹⁷ was used to visualize the alignments. Detailed PERL scripts and related database files and analyses in this study are available upon request.

For the analysis of the total RNA datasets, the samples were normalized to the total small RNAs including miRNAs, 22G-RNAs and 21U-RNAs. For ALG-1 bound miRNAs (IP), miRNA and miR* reads were normalized on miR-48-5p reads bound to ALG-1 as it binds ALG-1 WT, S642A and S642E equally (Figure S5A). Three replicates were used for statistical analysis.

Specific miRISC purification: 2'-O-methyl pull down—2'-O-methyl pull down¹¹⁸ were performed with adult animal lysates homogenized in 2 volumes of lysis buffer (100 mM potassium acetate, 30 mM Hepes-KOH pH 7, 2 mM magnesium acetate, 1 mM DTT, 1.5% [v/v] Triton X-100, 1 tablet/10 ml Complete Mini Protease Inhibitor without EDTA (Roche)) using a Dounce homogenizer. The extracts were clarified by centrifugation at 10,000x g. 4 mg of worm lysate was pre-cleared with M-280 streptavidin Dynabeads

(Thermo Fisher Scientific) coupled with non-specific 2'-*O*-Me Luciferase oligonucleotides (10pmol) for 1h. The supernatant was incubated with biotinylated 2'-*O*-Me oligonucleotides (10pmol) bound to streptavidin beads for 1h at room temperature. Beads were washed three times using ice-cold lysis buffer. Beads were resuspended in 20 μ L 2X SDS loading buffer and eluted by heating at 95°C for 10 min before loading on gel for western blotting. 2'-*O*-Me oligonucleotides for miR-35-3p pull-down and the non-specific oligonucleotides targeting luciferase are listed in Table S2.

In vitro phosphorylation assay—In vitro PKA kinase assays were performed using assay conditions adapted from the manufacturer's recommendations (Recombinant PKA, P6000S, NEB). All reactions were performed in a 25 μ L volume for 60 min at 30°C. Assay buffer was composed of 50 mM Tris-HCl (pH 7.5), 10 mM MgCl₂, 5 mM EGTA, 0.1 mM EDTA, 2 mM DTT, 0.01% Brij 35, 2 units of recombinant CK2, and 200 μ M [γ -³²P] ATP [6000 Ci/mmol; Perkin Elmer]. Reactions were terminated on ice using 7.5 mM Guanidine hydrochloride and the biotinylated peptides were spotted on streptavidin-coated membranes. Samples were washed three times in 2M NaCl followed by four times in 2M NaCl with 1% H₃PO₄. Incorporated ³²P was measured using a liquid scintillation counter in CPM (counts per minute). The data were also analyzed by Tricine-SDS-PAGE and autoradiography. Total protein levels of PKA were observed by Coomassie staining.

Cell culture and transfection—The vectors for Flag/HA-tagged human AGO2 as well as Flag/HA-tagged EGFP²³ and the AGO2 Y529E mutant⁴⁰ were used. S478 mutations were introduced by site-directed mutagenesis strategy using the primers in Table S2. Constructs were verified by Sanger sequencing.

HEK 293T cells were cultivated under standard conditions (37 °C, 5 % CO₂) using Dulbecco's modified Eagle Medium (DMEM, Gibco) supplemented with 10 % FBS (Sigma-Aldrich) and 1% penicillin-streptomycin (Sigma-Aldrich). Cells were grown on 15 cm dishes and calcium-phosphate transfected using 10 μ g of plasmid DNA per dish. For transfection of the AGO2 S478E mutant, 20 μ g of DNA were used, for transfection of EGFP 5 μ g.

For analysis of AGO2 target interactions, cells were harvested 48 h after transfection, washed with PBS and lysed in 1 mL NET buffer (50 mM Tris/HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.5 % (v/v) NP-40 alternative, 10 % glycerol, 1 mM NaF, 1 mM DTT and 1 mM AEBSF) for 20 min on ice. Lysates were cleared by centrifugation at 15,000 g for 20 min at 4 °C and input samples were taken before performing immunoprecipitation.

Immunoprecipitation (IP) of Flag/HA AGO2—For IP of Flag-tagged proteins and subsequent analysis of AGO2 target interaction, 50 μ L packed volume of ANTI-FLAG M2 agarose beads (Sigma-Aldrich) was used. Prior to use, beads were washed twice with cold PBS (1 min, 1,000 g, 4 °C). The beads were incubated with lysate for 2.5 h at 4 °C while rotating. Afterwards, the samples were washed with NET lysis buffer (50 mM Tris/HCl pH 7.5, 5 mM EDTA, 0.5 % NP-40 alternative, 10 % glycerol, 1 mM NaF, 1 mM DTT, 1 mM AEBSF) + 300 mM NaCl twice, once with lysis buffer + 450 mM NaCl, once with 600 mM

NaCl, once with 450 mM NaCl, followed by one washing step with PBS. During the last washing step, samples were split into RNA (75 %) and Western blot (25 %) samples.

After adding 50 μ l of 2.5 x Laemmli sample buffer to the Western blot samples, samples were incubated for 5 min at 95 °C. The denatured proteins were separated on a 10 % SDS gel and semidry blotted. Flag/HA-tagged AGO2 proteins were detected with anti-HA antibody (Covance 16B12, 1:1000) in combination with IRDye 800CW goat anti-mouse IgG secondary antibody (Li-Cor Biosciences, 1:10 000). Signals were detected and quantified with the Odyssey Imaging System (Li-Cor Biosciences).

mRNA quantification of and Flag/HA AGO2 IP transfected cells—RNA of input and IP samples was extracted using Trizol reagent (Thermo Fisher Scientific) according to the manufacturer's protocol, including a second extraction step with chloroform. 1 μ g of input and the complete RNA of IP samples were digested with DNaseI (Thermo Fisher Scientific), and cDNA was synthesized using the First-Strand cDNA synthesis kit (Thermo Fisher Scientific) with random hexamer primers following the manufacturer's protocol. RT-qPCR was performed with Takyon No Rox SYBR MasterMix dTTP Blue (Eurogentec) using the primers listed in Table S2. Data were analyzed using the $\Delta\Delta$ Ct method and normalized to the AGO2 expression in the Western blot IP sample.

Northern blot analysis of miRNA expression in Flag/HA AGO2 transfected cells—RNA of Flag/HA AGO2 transfected HEK 293T cells input samples was extracted using Trizol (Thermo Fisher Scientific) according to the manufacturer's protocol. Northern blots were performed with 1 μ g of input RNA¹¹⁹. RNA was separated on 12 % denaturing polyacrylamide gels (Rotiphorese, Roth), semidry blotted, EDC cross-linked, and hybridized overnight at 50°C. Blots were washed twice with 5 \times SSC, 1 % [w/v] SDS, and once with 1 \times SSC, 1 % [w/v] SDS. Signals were detected by exposure to a screen and scanning with the PMI imaging system (BioRad).

QUANTIFICATION AND STATISTICAL ANALYSIS

Experiments with *C. elegans*—Statistical analysis for phenotypes (Figure 1A, B and D; Figure 6D and E; Figure S1B-C) is presented as percentage of population scored and statistical significance was determined with a two-tailed Fisher's exact test in Excel. For the lifespan assay (Figure 1C), *P-values* were calculated with a Mantel-Cox log-rank test with GraphPad Prism. For developmental timing (Figure 2), *P-values* were calculated with a Welch two-sample and two-sided *t*-test. For Figure S2 and S3, read counts of each timepoint for each sample were divided by total number of reads and multiplied by the average library size. A pseudocount of 8 was added after log₂ transformation. Pearson's correlation was performed using *Seaborn* package in Python and PCA was performed using *sklearn.decomposition* package in python. Statistical analysis for miRNA quantification (Figure 4A, B and D; Figure 5A and C; Figure S4A; Figure S5A) was evaluated with a two-tailed Student's *t*-test in Excel. λ N/Box-B tethering reporter fluorescence intensity (Figure 3B) was quantified with Zen Software (Zeiss), presented as mean. *P-values* were calculated with a two-tailed Student's *t*-test in Excel. Western blot bands intensity (Figure 1C; Figure 5B; Figure S1D; Figure S5A) were measured with ImageJ software and *t*-test were used to

assess differences in protein levels where applicable, using biological triplicates. Statistical details, including the sample size (n) and the number of biological replicates for each experiment, can be found in the respective figure and figure legend. Normality and equal variance assumptions were not tested.

Experiments with human AGO2—Northern blot signals were quantified with the PMI software Quantity One, Western blot signals with the Odyssey software. Significance was tested using a two-tailed Student's t -test in Excel. All experiments were performed in three biological replicates. Data is shown as the mean and error bars represent the standard deviation.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

We would like to thank Dr. Weifeng Gu for the help with small RNA cloning and sequencing data analysis, Jean-Christophe Simard for technical help and Dr. Thomas Duchaine for providing DCR-1 antibody. We thank the members of our laboratory for helpful comments. The Canadian Institutes of Health Research (CIHR) supported this work. M.Q.H. and V.N.S. are recipients of scholarship from the Fonds de Recherche du Québec-Santé (FRQ-S). S.N. received funding from the EU Horizon 2020 Research and Innovation Program through a Marie Skłodowska-Curie grant (842386-miRhythm). H.G. received funding from the SNF through the NCCR "RNA & Disease" and the Novartis Research Foundation through the FMI. K.N. was supported by the National Institutes of Health (NIH; R01GM124320). G.M. received funding from the Deutsche Forschungsgemeinschaft (SFB 960).

REFERENCES

1. Lee RC, Feinbaum RL, and Ambros V (1993). The *C. elegans* heterochronic gene *lin-4* encodes small RNAs with antisense complementarity to *lin-14*. *Cell* 75, 843–854. 10.1016/0092-8674(93)90529-y. [PubMed: 8252621]
2. Wightman B, Ha I, and Ruvkun G (1993). Posttranscriptional regulation of the heterochronic gene *lin-14* by *lin-4* mediates temporal pattern formation in *C. elegans*. *Cell* 75, 855–862. 10.1016/0092-8674(93)90530-4. [PubMed: 8252622]
3. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR, and Ruvkun G (2000). The 21-nucleotide *let-7* RNA regulates developmental timing in *Caenorhabditis elegans*. *Nature* 403, 901–906. 10.1038/35002607. [PubMed: 10706289]
4. Peng Y, and Croce CM (2016). The role of MicroRNAs in human cancer. *Signal Transduct Target Ther* 1, 15004. 10.1038/sigtrans.2015.4. [PubMed: 29263891]
5. Chandra S, Vimal D, Sharma D, Rai V, Gupta SC, and Chowdhuri DK (2017). Role of miRNAs in development and disease: Lessons learnt from small organisms. *Life sciences* 185, 8–14. 10.1016/j.lfs.2017.07.017. [PubMed: 28728902]
6. Hajieghrari B, and Farrokhi N (2022). Plant RNA-mediated gene regulatory network. *Genomics* 114, 409–442. 10.1016/j.ygeno.2021.12.020. [PubMed: 34954000]
7. Kim VN, Han J, and Siomi MC (2009). Biogenesis of small RNAs in animals. *Nat Rev Mol Cell Biol* 10, 126–139. 10.1038/nrm2632. [PubMed: 19165215]
8. Ha M, and Kim VN (2014). Regulation of microRNA biogenesis. *Nat Rev Mol Cell Biol* 15, 509–524. 10.1038/nrm3838. [PubMed: 25027649]
9. Dueck A, and Meister G (2014). Assembly and function of small RNA - argonaute protein complexes. *Biol Chem* 395, 611–629. 10.1515/hsz-2014-0116. [PubMed: 24603840]
10. Kobayashi H, and Tomari Y (2016). RISC assembly: Coordination between small RNAs and Argonaute proteins. *Biochimica et biophysica acta* 1859, 71–81. 10.1016/j.bbagr.2015.08.007. [PubMed: 26303205]

11. Nakanishi K (2016). Anatomy of RISC: how do small RNAs and chaperones activate Argonaute proteins? *Wiley Interdiscip Rev RNA* 7, 637–660. 10.1002/wrna.1356. [PubMed: 27184117]
12. Ramachandran V, and Chen X (2008). Degradation of microRNAs by a family of exoribonucleases in *Arabidopsis*. *Science* 321, 1490–1492. 10.1126/science.1163728. [PubMed: 18787168]
13. Chatterjee S, and Grosshans H (2009). Active turnover modulates mature microRNA activity in *Caenorhabditis elegans*. *Nature* 461, 546–549. 10.1038/nature08349. [PubMed: 19734881]
14. Chatterjee S, Fasler M, Bussing I, and Grosshans H (2011). Target-mediated protection of endogenous microRNAs in *C. elegans*. *Dev Cell* 20, 388–396. 10.1016/j.devcel.2011.02.008. [PubMed: 21397849]
15. Medley JC, Panzade G, and Zinovyeva AY (2021). microRNA strand selection: Unwinding the rules. *Wiley Interdiscip Rev RNA* 12, e1627. 10.1002/wrna.1627. [PubMed: 32954644]
16. Jonas S, and Izaurralde E (2015). Towards a molecular understanding of microRNA-mediated gene silencing. *Nat Rev Genet* 16, 421–433. 10.1038/nrg3965. [PubMed: 26077373]
17. Frederick PM, and Simard MJ (2021). Regulation and different functions of the animal microRNA-induced silencing complex. *Wiley Interdiscip Rev RNA* 13, e1701. 10.1002/wrna.1701. [PubMed: 34725940]
18. Grishok A, Pasquinelli AE, Conte D, Li N, Parrish S, Ha I, Baillie DL, Fire A, Ruvkun G, and Mello CC (2001). Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control *C. elegans* developmental timing. *Cell* 106, 23–34. 10.1016/S0092-8674(01)00431-7. [PubMed: 11461699]
19. Vasquez-Rifo A, Jannot G, Armisen J, Labouesse M, Bukhari SI, Rondeau EL, Miska EA, and Simard MJ (2012). Developmental characterization of the microRNA-specific *C. elegans* Argonautes alg-1 and alg-2. *PLoS One* 7, e33750. 10.1371/journal.pone.0033750. [PubMed: 22448270]
20. Brown KC, Svendsen JM, Tucci RM, Montgomery BE, and Montgomery TA (2017). ALG-5 is a miRNA-associated Argonaute required for proper developmental timing in the *Caenorhabditis elegans* germline. *Nucleic Acids Res* 45, 9093–9107. 10.1093/nar/gkx536. [PubMed: 28645154]
21. Nakanishi K (2022). Anatomy of four human Argonaute proteins. *Nucleic Acids Res* 50, 6618–6638. 10.1093/nar/gkac519. [PubMed: 35736234]
22. Nakanishi K, Weinberg DE, Bartel DP, and Patel DJ (2012). Structure of yeast Argonaute with guide RNA. *Nature* 486, 368–374. 10.1038/nature11211. [PubMed: 22722195]
23. Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, and Tuschl T (2004). Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. *Mol Cell* 15, 185–197. 10.1016/j.molcel.2004.07.007. [PubMed: 15260970]
24. Liu J, Carnell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, Hammond SM, Joshua-Tor L, and Hannon GJ (2004). Argonaute2 is the catalytic engine of mammalian RNAi. *Science* 305, 1437–1441. 10.1126/science.1102513. [PubMed: 15284456]
25. Park MS, Phan HD, Busch F, Hinckley SH, Brackbill JA, Wsocki VH, and Nakanishi K (2017). Human Argonaute3 has slicer activity. *Nucleic Acids Res* 45, 11867–11877. 10.1093/nar/gkx916. [PubMed: 29040713]
26. Bouasker S, and Simard MJ (2012). The slicing activity of miRNA-specific Argonautes is essential for the miRNA pathway in *C. elegans*. *Nucleic Acids Res* 40, 10452–10462. 10.1093/nar/gks748. [PubMed: 22904066]
27. Schirle NT, and MacRae IJ (2012). The crystal structure of human Argonaute2. *Science* 336, 1037–1040. 10.1126/science.1221551. [PubMed: 22539551]
28. Till S, Lejeune E, Thermann R, Bortfeld M, Hothorn M, Enderle D, Heinrich C, Hentze MW, and Ladurner AG (2007). A conserved motif in Argonaute-interacting proteins mediates functional interactions through the Argonaute PIWI domain. *Nat Struct Mol Biol* 14, 897–903. 10.1038/nsmb1302. [PubMed: 17891150]
29. Lian SL, Li S, Abadal GX, Pauley BA, Fritzler MJ, and Chan EK (2009). The C-terminal half of human Ago2 binds to multiple GW-rich regions of GW182 and requires GW182 to mediate silencing. *RNA* 15, 804–813. 10.1261/rna.1229409. [PubMed: 19324964]

30. Lazzaretti D, Tournier I, and Izaurralde E (2009). The C-terminal domains of human TNRC6A, TNRC6B, and TNRC6C silence bound transcripts independently of Argonaute proteins. *RNA* 15, 1059–1066. 10.1261/rna.1606309. [PubMed: 19383768]
31. Takimoto K, Wakiyama M, and Yokoyama S (2009). Mammalian GW182 contains multiple Argonaute-binding sites and functions in microRNA-mediated translational repression. *RNA* 15, 1078–1089. 10.1261/rna.1363109. [PubMed: 19398495]
32. Qi HH, Ongusaha PP, Myllyharju J, Cheng D, Pakkanen O, Shi Y, Lee SW, Peng J, and Shi Y (2008). Prolyl 4-hydroxylation regulates Argonaute 2 stability. *Nature* 455, 421–424. 10.1038/nature07186. [PubMed: 18690212]
33. Shen J, Xia W, Khotskaya YB, Huo L, Nakanishi K, Lim SO, Du Y, Wang Y, Chang WC, Chen CH, et al. (2013). EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. *Nature* 497, 383–387. 10.1038/nature12080. [PubMed: 23636329]
34. Yang M, Haase AD, Huang FK, Coulis G, Rivera KD, Dickinson BC, Chang CJ, Pappin DJ, Neubert TA, Hannon GJ, et al. (2014). Dephosphorylation of tyrosine 393 in argonaute 2 by protein tyrosine phosphatase 1B regulates gene silencing in oncogenic RAS-induced senescence. *Mol Cell* 55, 782–790. 10.1016/j.molcel.2014.07.018. [PubMed: 25175024]
35. Leung AK, Vyas S, Rood JE, Bhutkar A, Sharp PA, and Chang P (2011). Poly(ADP-ribose) regulates stress responses and microRNA activity in the cytoplasm. *Mol Cell* 42, 489–499. 10.1016/j.molcel.2011.04.015. [PubMed: 21596313]
36. Horman SR, Janas MM, Litterst C, Wang B, MacRae IJ, Sever MJ, Morrissey DV, Graves P, Luo B, Umeshima S, et al. (2013). Akt-mediated phosphorylation of argonaute 2 downregulates cleavage and upregulates translational repression of MicroRNA targets. *Mol Cell* 50, 356–367. 10.1016/j.molcel.2013.03.015. [PubMed: 23603119]
37. Zeng Y, Sankala H, Zhang X, and Graves PR (2008). Phosphorylation of Argonaute 2 at serine-387 facilitates its localization to processing bodies. *Biochem J* 413, 429–436. 10.1042/BJ20080599. [PubMed: 18476811]
38. Bridge KS, Shah KM, Li Y, Foxler DE, Wong SCK, Miller DC, Davidson KM, Foster JG, Rose R, Hodgkinson MR, et al. (2017). Argonaute Utilization for miRNA Silencing Is Determined by Phosphorylation-Dependent Recruitment of LIM-Domain-Containing Proteins. *Cell Rep* 20, 173–187. 10.1016/j.celrep.2017.06.027. [PubMed: 28683311]
39. Paradis-Isler N, and Boehm J (2018). NMDA receptor-dependent dephosphorylation of serine 387 in Argonaute 2 increases its degradation and affects dendritic spine density and maturation. *The Journal of biological chemistry* 293, 9311–9325. 10.1074/jbc.RA117.001007. [PubMed: 29735530]
40. Rüdél S, Wang Y, Lenobel R, Korner R, Hsiao HH, Urlaub H, Patel D, and Meister G (2011). Phosphorylation of human Argonaute proteins affects small RNA binding. *Nucleic Acids Res* 39, 2330–2343. 10.1093/nar/gkq1032. [PubMed: 21071408]
41. Quévillon Huberdeau M, Zeitler DM, Hauptmann J, Bruckmann A, Fressigne L, Danner J, Piquet S, Strieder N, Engelmann JC, Jannot G, et al. (2017). Phosphorylation of Argonaute proteins affects mRNA binding and is essential for microRNA-guided gene silencing in vivo. *EMBO J* 36, 2088–2106. 10.15252/embj.201696386. [PubMed: 28645918]
42. Golden RJ, Chen B, Li T, Braun J, Manjunath H, Chen X, Wu J, Schmid V, Chang TC, Kopp F, et al. (2017). An Argonaute phosphorylation cycle promotes microRNA-mediated silencing. *Nature* 542, 197–202. 10.1038/nature21025. [PubMed: 28114302]
43. Slack FJ, Basson M, Liu Z, Ambros V, Horvitz HR, and Ruvkun G (2000). The lin-41 RBCC gene acts in the *C. elegans* heterochronic pathway between the let-7 regulatory RNA and the LIN-29 transcription factor. *Mol Cell* 5, 659–669. 10.1016/s1097-2765(00)80245-2. [PubMed: 10882102]
44. Ecsedi M, Rausch M, and Grosshans H (2015). The let-7 microRNA directs vulval development through a single target. *Dev Cell* 32, 335–344. 10.1016/j.devcel.2014.12.018. [PubMed: 25669883]
45. Kato M, Chen X, Inukai S, Zhao H, and Slack FJ (2011). Age-associated changes in expression of small, noncoding RNAs, including microRNAs, in *C. elegans*. *RNA* 17, 1804–1820. 10.1261/rna.2714411. [PubMed: 21810936]

46. Aalto AP, Nicastro IA, Broughton JP, Chipman LB, Schreiner WP, Chen JS, and Pasquinelli AE (2018). Opposing roles of microRNA Argonautes during *Caenorhabditis elegans* aging. *PLoS genetics* 14, e1007379. 10.1371/journal.pgen.1007379. [PubMed: 29927939]
47. Boehm M, and Slack F (2005). A developmental timing microRNA and its target regulate life span in *C. elegans*. *Science* 310, 1954–1957. 10.1126/science.1115596. [PubMed: 16373574]
48. de Lencastre A, Pincus Z, Zhou K, Kato M, Lee SS, and Slack FJ (2010). MicroRNAs both promote and antagonize longevity in *C. elegans*. *Curr Biol* 20, 2159–2168. 10.1016/j.cub.2010.11.015. [PubMed: 21129974]
49. Pincus Z, Smith-Vikos T, and Slack FJ (2011). MicroRNA predictors of longevity in *Caenorhabditis elegans*. *PLoS genetics* 7, e1002306. 10.1371/journal.pgen.1002306. [PubMed: 21980307]
50. Boulias K, and Horvitz HR (2012). The *C. elegans* microRNA mir-71 acts in neurons to promote germline-mediated longevity through regulation of DAF-16/FOXO. *Cell Metab* 15, 439–450. 10.1016/j.cmet.2012.02.014. [PubMed: 22482727]
51. Smith-Vikos T, de Lencastre A, Inukai S, Shlomchik M, Holtrup B, and Slack FJ (2014). MicroRNAs mediate dietary-restriction-induced longevity through PHA-4/FOXA and SKN-1/Nrf transcription factors. *Curr Biol* 24, 2238–2246. 10.1016/j.cub.2014.08.013. [PubMed: 25242029]
52. Frank F, Sonenberg N, and Nagar B (2010). Structural basis for 5'-nucleotide base-specific recognition of guide RNA by human AGO2. *Nature* 465, 818–822. 10.1038/nature09039. [PubMed: 20505670]
53. Boland A, Tritschler F, Heimstadt S, Izaurrealde E, and Weichenrieder O (2010). Crystal structure and ligand binding of the MID domain of a eukaryotic Argonaute protein. *EMBO Rep* 11, 522–527. 10.1038/embor.2010.81. [PubMed: 20539312]
54. Ketting RF, and Cochella L (2021). Concepts and functions of small RNA pathways in *C. elegans*. *Curr Top Dev Biol* 144, 45–89. 10.1016/bs.ctdb.2020.08.002. [PubMed: 33992161]
55. Olmedo M, Geibel M, Artal-Sanz M, and Merrow M (2015). A High-Throughput Method for the Analysis of Larval Developmental Phenotypes in *Caenorhabditis elegans*. *Genetics* 201, 443–448. 10.1534/genetics.115.179242. [PubMed: 26294666]
56. Meeuse MW, Hauser YP, Morales Moya LJ, Hendriks GJ, Eglinger J, Bogaarts G, Tsiairis C, and Grosshans H (2020). Developmental function and state transitions of a gene expression oscillator in *Caenorhabditis elegans*. *Mol Syst Biol* 16, e9975. 10.15252/msb.209975. [PubMed: 33438821]
57. Jannot G, Michaud P, Quevillon Huberdeau M, Morel-Berryman L, Brackbill JA, Piquet S, McJunkin K, Nakanishi K, and Simard MJ (2016). GW182-Free microRNA Silencing Complex Controls Post-transcriptional Gene Expression during *Caenorhabditis elegans* Embryogenesis. *PLoS genetics* 12, e1006484. 10.1371/journal.pgen.1006484. [PubMed: 27935964]
58. Gregory RI, Chendrimada TP, Cooch N, and Shiekhattar R (2005). Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. *Cell* 123, 631–640. 10.1016/j.cell.2005.10.022. [PubMed: 16271387]
59. Diederichs S, and Haber DA (2007). Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression. *Cell* 131, 1097–1108. 10.1016/j.cell.2007.10.032. [PubMed: 18083100]
60. Park JH, and Shin C (2015). Slicer-independent mechanism drives small-RNA strand separation during human RISC assembly. *Nucleic Acids Res* 43, 9418–9433. 10.1093/nar/gkv937. [PubMed: 26384428]
61. Alvarez-Saavedra E, and Horvitz HR (2010). Many families of *C. elegans* microRNAs are not essential for development or viability. *Curr Biol* 20, 367–373. 10.1016/j.cub.2009.12.051. [PubMed: 20096582]
62. Shaw WR, Armisen J, Lehrbach NJ, and Miska EA (2010). The conserved miR-51 microRNA family is redundantly required for embryonic development and pharynx attachment in *Caenorhabditis elegans*. *Genetics* 185, 897–905. 10.1534/genetics.110.117515. [PubMed: 20421599]
63. McJunkin K, and Ambros V (2014). The embryonic mir-35 family of microRNAs promotes multiple aspects of fecundity in *Caenorhabditis elegans*. *G3 (Bethesda)* 4, 1747–1754. 10.1534/g3.114.011973. [PubMed: 25053708]

64. Ghini F, Rubolino C, Climent M, Simeone I, Marzi MJ, and Nicassio F (2018). Endogenous transcripts control miRNA levels and activity in mammalian cells by target-directed miRNA degradation. *Nature Communications* 9, 3119. 10.1038/s41467-018-05182-9.
65. Sheu-Gruttadauria J, Pawlica P, Klum SM, Wang S, Yario TA, Schirle Oakdale NT, Steitz JA, and MacRae IJ (2019). Structural Basis for Target-Directed MicroRNA Degradation. *Mol Cell* 75, 1243–1255. 10.1016/j.molcel.2019.06.019. [PubMed: 31353209]
66. Han J, LaVigne CA, Jones BT, Zhang H, Gillett F, and Mendell JT (2020). A ubiquitin ligase mediates target-directed microRNA decay independently of tailing and trimming. *Science* 370, eabc9546. 10.1126/science.abc9546. [PubMed: 33184234]
67. Shi CY, Kingston ER, Kleaveland B, Lin DH, Stubna MW, and Bartel DP (2020). The ZSWIM8 ubiquitin ligase mediates target-directed microRNA degradation. *Science* 370, eabc9359. 10.1126/science.abc9359. [PubMed: 33184237]
68. Blom N, Gammeltoft S, and Brunak S (1999). Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. *J Mol Biol* 294, 1351–1362. 10.1006/jmbi.1999.3310. [PubMed: 10600390]
69. Gross RE, Bagchi S, Lu X, and Rubin CS (1990). Cloning, characterization, and expression of the gene for the catalytic subunit of cAMP-dependent protein kinase in *Caenorhabditis elegans*. Identification of highly conserved and unique isoforms generated by alternative splicing. *The Journal of biological chemistry* 265, 6896–6907. [PubMed: 2324104]
70. Pastok MW, Prescott MC, Dart C, Murray P, Rees HH, and Fisher MJ (2013). Structural diversity of the cAMP-dependent protein kinase regulatory subunit in *Caenorhabditis elegans*. *Cell Signal* 25, 168–177. 10.1016/j.cellsig.2012.09.006. [PubMed: 22975687]
71. Sjøberg K, and Skalhogg BS (2018). The Molecular Basis for Specificity at the Level of the Protein Kinase a Catalytic Subunit. *Front Endocrinol (Lausanne)* 9, 538. 10.3389/fendo.2018.00538. [PubMed: 30258407]
72. Buechler YJ, Herberg FW, and Taylor SS (1993). Regulation-defective mutants of type I cAMP-dependent protein kinase. Consequences of replacing arginine 94 and arginine 95. *The Journal of biological chemistry* 268, 16495–16503. [PubMed: 8393867]
73. Schade MA, Reynolds NK, Dollins CM, and Miller KG (2005). Mutations that rescue the paralysis of *Caenorhabditis elegans* ric-8 (synembryon) mutants activate the G alpha(s) pathway and define a third major branch of the synaptic signaling network. *Genetics* 169, 631–649. 10.1534/genetics.104.032334. [PubMed: 15489510]
74. Elkayam E, Kuhn CD, Tocilj A, Haase AD, Greene EM, Hannon GJ, and Joshua-Tor L (2012). The structure of human argonaute-2 in complex with miR-20a. *Cell* 150, 100–110. 10.1016/j.cell.2012.05.017. [PubMed: 22682761]
75. Faehnle CR, Elkayam E, Haase AD, Hannon GJ, and Joshua-Tor L (2013). The making of a slicer: activation of human Argonaute-1. *Cell Rep* 3, 1901–1909. 10.1016/j.celrep.2013.05.033. [PubMed: 23746446]
76. Nakanishi K, Ascano M, Gogakos T, Ishibe-Murakami S, Serganov AA, Briskin D, Morozov P, Tuschl T, and Patel DJ (2013). Eukaryote-specific insertion elements control human ARGONAUTE slicer activity. *Cell Rep* 3, 1893–1900. 10.1016/j.celrep.2013.06.010. [PubMed: 23809764]
77. Schirle NT, Sheu-Gruttadauria J, and MacRae IJ (2014). Structural basis for microRNA targeting. *Science* 346, 608–613. 10.1126/science.1258040. [PubMed: 25359968]
78. Sheu-Gruttadauria J, Xiao Y, Gebert LF, and MacRae IJ (2019). Beyond the seed: structural basis for supplementary microRNA targeting by human Argonaute2. *EMBO J* 38, e101153. 10.15252/embj.2018101153. [PubMed: 31268608]
79. Park MS, Araya-Secchi R, Brackbill JA, Phan HD, Kehling AC, Abd El-Wahab EW, Dayeh DM, Sotomayor M, and Nakanishi K (2019). Multidomain Convergence of Argonaute during RISC Assembly Correlates with the Formation of Internal Water Clusters. *Mol Cell* 75, 725–740 e726. 10.1016/j.molcel.2019.06.011. [PubMed: 31324450]
80. Zinovyeva AY, Bouasker S, Simard MJ, Hammell CM, and Ambros V (2014). Mutations in conserved residues of the *C. elegans* microRNA Argonaute ALG-1 identify separable

- functions in ALG-1 miRISC loading and target repression. *PLoS genetics* 10, e1004286. 10.1371/journal.pgen.1004286. [PubMed: 24763381]
81. Zinovyeva AY, Veksler-Lublinsky I, Vashisht AA, Wohlschlegel JA, and Ambros VR (2015). *Caenorhabditis elegans* ALG-1 antimorphic mutations uncover functions for Argonaute in microRNA guide strand selection and passenger strand disposal. *Proceedings of the National Academy of Sciences of the United States of America* 112, E5271–5280. 10.1073/pnas.1506576112. [PubMed: 26351692]
 82. Johnston M, Geoffroy MC, Sobala A, Hay R, and Hutvagner G (2010). HSP90 protein stabilizes unloaded argonaute complexes and microscopic P-bodies in human cells. *Molecular biology of the cell* 21, 1462–1469. 10.1091/mbc.E09-10-0885. [PubMed: 20237157]
 83. Derrien B, Baumberger N, Schepetilnikov M, Viotti C, De Cillia J, Ziegler-Graff V, Isono E, Schumacher K, and Genschik P (2012). Degradation of the antiviral component ARGONAUTE1 by the autophagy pathway. *Proceedings of the National Academy of Sciences of the United States of America* 109, 15942–15946. 10.1073/pnas.1209487109. [PubMed: 23019378]
 84. Smibert P, Yang JS, Azzam G, Liu JL, and Lai EC (2013). Homeostatic control of Argonaute stability by microRNA availability. *Nat Struct Mol Biol* 20, 789–795. 10.1038/nsmb.2606. [PubMed: 23708604]
 85. Kobayashi H, Shoji K, Kiyokawa K, Negishi L, and Tomari Y (2019). VCP Machinery Mediates Autophagic Degradation of Empty Argonaute. *Cell Rep* 28, 1144–1153 e1144. 10.1016/j.celrep.2019.07.003. [PubMed: 31365860]
 86. Kobayashi H, Shoji K, Kiyokawa K, Negishi L, and Tomari Y (2019). Iruka Eliminates Dysfunctional Argonaute by Selective Ubiquitination of Its Empty State. *Mol Cell* 73, 119–129. 10.1016/j.molcel.2018.10.033. [PubMed: 30503771]
 87. Majercak J, Kalderon D, and Ederly I (1997). *Drosophila melanogaster* deficient in protein kinase A manifests behavior-specific arrhythmia but normal clock function. *Molecular and cellular biology* 17, 5915–5922. 10.1128/MCB.17.10.5915. [PubMed: 9315649]
 88. Wang H, and Sieburth D (2013). PKA controls calcium influx into motor neurons during a rhythmic behavior. *PLoS genetics* 9, e1003831. 10.1371/journal.pgen.1003831. [PubMed: 24086161]
 89. Liu F, Xiao Y, Ji XL, Zhang KQ, and Zou CG (2017). The cAMP-PKA pathway-mediated fat mobilization is required for cold tolerance in *C. elegans*. *Sci Rep* 7, 638. 10.1038/s41598-017-00630-w. [PubMed: 28377576]
 90. Gottschling DC, Doring F, and Luersen K (2017). Locomotion Behavior Is Affected by the GalphaS Pathway and the Two-Pore-Domain K(+) Channel TWK-7 Interacting in GABAergic Motor Neurons in *Caenorhabditis elegans*. *Genetics* 206, 283–297. 10.1534/genetics.116.195669. [PubMed: 28341653]
 91. Xiao Y, Liu F, Zhao PJ, Zou CG, and Zhang KQ (2017). PKA/KIN-1 mediates innate immune responses to bacterial pathogens in *Caenorhabditis elegans*. *Innate immunity* 23, 656–666. 10.1177/1753425917732822. [PubMed: 28958206]
 92. Castaneda PG, Cecchetelli AD, Pettit HN, and Cram EJ (2020). Galpha/GSA-1 works upstream of PKA/KIN-1 to regulate calcium signaling and contractility in the *Caenorhabditis elegans* spermatheca. *PLoS genetics* 16, e1008644. 10.1371/journal.pgen.1008644. [PubMed: 32776941]
 93. Zhang H, Kong Q, Wang J, Jiang Y, and Hua H (2020). Complex roles of cAMP-PKA-CREB signaling in cancer. *Exp Hematol Oncol* 9, 32. 10.1186/s40164-020-00191-1. [PubMed: 33292604]
 94. Ranganathan G, Pokrovskaya I, Ranganathan S, and Kern PA (2005). Role of A kinase anchor proteins in the tissue-specific regulation of lipoprotein lipase. *Molecular endocrinology* 19, 2527–2534. 10.1210/me.2005-0144. [PubMed: 15961507]
 95. Tudisca V, Simpson C, Castelli L, Lui J, Hoyle N, Moreno S, Ashe M, and Portela P (2012). PKA isoforms coordinate mRNA fate during nutrient starvation. *Journal of cell science* 125, 5221–5232. 10.1242/jcs.111534. [PubMed: 22899713]
 96. Jewell JL, Fu V, Hong AW, Yu FX, Meng D, Melick CH, Wang H, Lam WM, Yuan HX, Taylor SS, and Guan KL (2019). GPCR signaling inhibits mTORC1 via PKA phosphorylation of Raptor. *eLife* 8, e43038. 10.7554/eLife.43038. [PubMed: 31112131]

97. Rataj F, Planel S, Desroches-Castan A, Le Douce J, Lamribet K, Denis J, Feige JJ, and Cherradi N (2016). The cAMP pathway regulates mRNA decay through phosphorylation of the RNA-binding protein TIS11b/BRF1. *Molecular biology of the cell* 27, 3841–3854. 10.1091/mbc.E16-06-0379. [PubMed: 27708140]
98. Venkatesh SR, and Singh V (2021). G protein-coupled receptors: The choreographers of innate immunity in *Caenorhabditis elegans*. *PLoS Pathog* 17, e1009151. 10.1371/journal.ppat.1009151. [PubMed: 33476324]
99. Somale D, Di Nardo G, di Blasio L, Puliavito A, Vara-Messler M, Chiaverina G, Palmiero M, Monica V, Gilardi G, Primo L, and Gagliardi PA (2020). Activation of RSK by phosphomimetic substitution in the activation loop is prevented by structural constraints. *Sci Rep* 10, 591. 10.1038/s41598-019-56937-3. [PubMed: 31953410]
100. Kozelekova A, Naplavova A, Brom T, Gasparik N, Simek J, Houser J, and Hritz J (2022). Phosphorylated and Phosphomimicking Variants May Differ-A Case Study of 14-3-3 Protein. *Front Chem* 10, 835733. 10.3389/fchem.2022.835733. [PubMed: 35321476]
101. Brenner S (1974). The genetics of *Caenorhabditis elegans*. *Genetics* 77, 71–94. [PubMed: 4366476]
102. Mello CC, Kramer JM, Stinchcomb D, and Ambros V (1991). Efficient gene transfer in *C.elegans*: extrachromosomal maintenance and integration of transforming sequences. *EMBO J* 10, 3959–3970. 10.1002/j.1460-2075.1991.tb04966.x. [PubMed: 1935914]
103. Paix A, Folkmann A, Rasoloson D, and Seydoux G (2015). High Efficiency, Homology-Directed Genome Editing in *Caenorhabditis elegans* Using CRISPR-Cas9 Ribonucleoprotein Complexes. *Genetics* 201, 47–54. 10.1534/genetics.115.179382. [PubMed: 26187122]
104. Timmons L, Court DL, and Fire A (2001). Ingestion of bacterially expressed dsRNAs can produce specific and potent genetic interference in *Caenorhabditis elegans*. *Gene* 263, 103–112. 10.1016/s0378-1119(00)00579-5. [PubMed: 11223248]
105. Duchaine TF, Wohlschlegel JA, Kennedy S, Bei Y, Conte D Jr., Pang K, Brownell DR, Harding S, Mitani S, Ruvkun G, et al. (2006). Functional proteomics reveals the biochemical niche of *C. elegans* DCR-1 in multiple small-RNA-mediated pathways. *Cell* 124, 343–354. 10.1016/j.cell.2005.11.036. [PubMed: 16439208]
106. Bethke A, Fielenbach N, Wang Z, Mangelsdorf DJ, and Antebi A (2009). Nuclear hormone receptor regulation of microRNAs controls developmental progression. *Science* 324, 95–98. 10.1126/science.1164899. [PubMed: 19342589]
107. Martin M (2011). Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet journal* 17, 10–12 (2011). 10.14806/ej.17.1.200.
108. Langmead B, Trapnell C, Pop M, and Salzberg SL (2009). Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol* 10, R25. 10.1186/gb-2009-10-3-r25. [PubMed: 19261174]
109. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, and Genome Project Data Processing, S. (2009). The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25, 2078–2079. 10.1093/bioinformatics/btp352. [PubMed: 19505943]
110. Harris TW, Arnaboldi V, Cain S, Chan J, Chen WJ, Cho J, Davis P, Gao S, Grove CA, Kishore R, et al. (2020). WormBase: a modern Model Organism Information Resource. *Nucleic Acids Res* 48, D762–D767. 10.1093/nar/gkz920. [PubMed: 31642470]
111. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, and Enright AJ (2006). miRBase: microRNA sequences, targets and gene nomenclature. *Nucleic Acids Res* 34, D140–144. 10.1093/nar/gkj112. [PubMed: 16381832]
112. Anders S, Pyl PT, and Huber W (2015). HTSeq—a Python framework to work with high-throughput sequencing data. *Bioinformatics* 31, 166–169. 10.1093/bioinformatics/btu638. [PubMed: 25260700]
113. Li L, Dai H, Nguyen AP, and Gu W (2020). A convenient strategy to clone small RNA and mRNA for high-throughput sequencing. *RNA* 26, 218–227. 10.1261/rna.071605.119. [PubMed: 31754076]

114. Chaves DA, Dai H, Li L, Moresco JJ, Oh ME, Conte D Jr., Yates JR 3rd, Mello CC, and Gu W (2021). The RNA phosphatase PIR-1 regulates endogenous small RNA pathways in *C. elegans*. *Mol Cell* 81, 546–557. 10.1016/j.molcel.2020.12.004. [PubMed: 33378643]
115. Jurka J, Kapitonov VV, Pavlicek A, Klonowski P, Kohany O, and Walichiewicz J (2005). Repbase Update, a database of eukaryotic repetitive elements. *Cytogenet Genome Res* 110, 462–467. 10.1159/000084979. [PubMed: 16093699]
116. Kozomara A, and Griffiths-Jones S (2011). miRBase: integrating microRNA annotation and deep-sequencing data. *Nucleic Acids Res* 39, D152–157. 10.1093/nar/gkq1027. [PubMed: 21037258]
117. Stein LD, Mungall C, Shu S, Caudy M, Mangone M, Day A, Nickerson E, Stajich JE, Harris TW, Arva A, and Lewis S (2002). The generic genome browser: a building block for a model organism system database. *Genome Res* 12, 1599–1610. 10.1101/gr.403602. [PubMed: 12368253]
118. Jannot G, Vasquez-Rifo A, and Simard MJ (2011). Argonaute pull-down and RISC analysis using 2'-O-methylated oligonucleotides affinity matrices. *Methods Mol Biol* 725, 233–249. 10.1007/978-1-61779-046-1_16. [PubMed: 21528458]
119. Pall GS, and Hamilton AJ (2008). Improved northern blot method for enhanced detection of small RNA. *Nat Protoc* 3, 1077–1084. 10.1038/nprot.2008.67. [PubMed: 18536652]




Figure 1. Phospho-mimicking ALG-1 S642E impairs *C. elegans* development.

(A) Edited ALG-1 of serine 642 (S642), into non-phosphorylatable alanine (A) and phospho-mimicking glutamate (E) mutant animals were monitored with Nomarski DIC microscopy to evaluate the incidence of alae formation defects at young adult stage. The graph indicates the percentage of animals affected by alae defects. *P*-values were measured with a two-tailed Fisher's exact test, ** indicates $p < 0.01$ and *** $p < 0.001$. The sample size (n) used for quantification is indicated. (B) Lethality through vulva bursting. Percentage of *alg-1(0)*, *alg-1(S642A)* and *alg-1(S642E)* animal populations that burst through the vulva when reaching adulthood. *P*-values were measured with a two-tailed Fisher's exact test, ** indicates $p < 0.01$ and *** $p < 0.001$. The sample size (n) used for quantification is indicated. (C) **Top:** Lifespan assay. Survival curves of wild-type (WT) animals (black), *alg-1(S642A)* (green), *alg-1(S642E)* (blue) and *alg-1(0)* (red). *P*-values were calculated using the Mantel-Cox log-rank test, ****: $p < 0.0001$ and **: $p < 0.01$. Lifespan assays were performed with a population of $n > 70$ animals for each genotype. **Bottom:** Western blot analysis of ALG-1 at L4 larval stage, two days into adulthood (2d) and five days into adulthood (5d). Exactly 75 worms were used for each genotype and time point. Actin was used as a loading control. The ratios of ALG-1 levels relative to wild-type animals at L4 stage after normalization on Actin levels are shown. This is representative of three biological replicates. (D) Embryonic

lethality. Embryos that die during development (unhatched) are counted and reported on the total progeny as a percentage. For each genotype, 8 P0 animals were allowed to lay eggs for 24h before removing them from their respective plate. After 48 hours, unhatched eggs and the total progeny (embryos and larvae) were counted. The boxplot reports the percentage of unhatched eggs relative to the total progeny for the indicated genotypes. *P*-values were measured by a two-tailed Fisher's exact test accounting for the total number of unhatched eggs and progeny of each P0 animal for each genotype. *: $p < 0.05$ and ***: $p < 0.001$.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 2. ALG-1 phosphorylation mutants affect larval developmental timing.

Quantification of developmental durations of single animal molts expressing the *xeSi296* transgene (A), intermolts (B) and larval stages (C) in WT ($n=64$), *alg-1(S642A)* ($n=68$) and *alg-1(S642E)* ($n=68$) as determined by a luciferase assay. The boxplot represents median (thick black line within the box), interquartile range (box), 1.5 times the interquartile range (whiskers); data falling outside this range are plotted as outliers (circles). P -values were measured by Welch two-sample and two-sided t-test. Asterisks represent statistically significant (* $p<0.05$, ** $p<0.01$, *** $p<0.001$).




Figure 3. Phosphorylation of ALG-1 serine 642 does not affect its interaction with GW182 homolog AIN-1 nor its ability to silence a mRNA.

(A) ALG-1 co-immunoprecipitation with GW182 homolog AIN-1. ALG-1 was immunoprecipitated from adult extract of wild type, *alg-1(S642A)* or *alg-1(S642E)* and polyclonal antibodies for AIN-1 and ALG-1 were used for western blotting. The inputs are 10% of the total protein extracts used for immunoprecipitations. Actin served as loading control. The blots are representative of three biological replicates. (B) ALG-1 S642 phosphorylation does not impair mRNA silencing when tethered to a mRNA 3' UTR.

Top left: Schematic representation of AGO tethering system. A GFP reporter under the control of an *alg-1* promoter fused with the sequence of *cog-1* 3' UTR where the *lisy-6* miRNA binding sites (delta *lisy-6* bs) are replaced by six copies of the Box-B element (x6: Box-B). The high affinity between the Box-B RNA secondary structure and the λN peptide fused to ALG-1 leads to its recruitment. A strain with a single integrated copy of *alg-1p::GFP::Box-B* reporter carrying endogenous *alg-1* alleles tagged with a λN sequence at the 5' end of the coding sequence was used to edit $\lambda N::alg-1$ into non-phosphorylatable $\lambda N::alg-1$ (S642A) and phospho-mimicking $\lambda N::alg-1$ (S642E). The expression level of the GFP reporter was measured in the pharynx. **Bottom left:** The GFP level expressed in the pharynx of young adult worms was quantified using arbitrary units (AU). The error bars represent the 95% confidence interval, and the *P*-values indicated were measured by a two-tailed Student's *t*-test; ****p*<0.001. The number of animals scored (*n*) is indicated and

the graph is representative of two independent measurements. **Right:** Representative images of animals expressing only the GFP reporter (\emptyset) or GFP reporter and different versions of λ N-tagged *alg-1* ($\lambda N::alg-1$) gene are shown. The scale bar indicates 20 μ m. Images were obtained at the same time of exposure, on the same slide, and with the same area of measure for each animal strain.




Figure 4. microRNA abundance is altered in phospho-mimicking ALG-1 S642E.

(A and B) Normalized miRNA reads expressed as \log_2 of reads per million (RPM) sequenced from small RNA cloning total RNA extracts of (A) *alg-1(S642A)* mutant animals and (B) *alg-1(S642E)* mutant animals compared to wild-type animals at adult stage. The scatterplot reports the guide miRNA (Left) and passenger strand miRNA (miR*) (Right) abundance in mutant vs wild-type animals. The abscissa measures the abundance in wild-type animals and the ordinate measures the abundance in *alg-1(S642A)* or *alg-1(S642E)*. Each point represents the values for a specific miRNA averaged on three biological replicates. Red squares are miRNAs for which the difference in number of normalized reads compared to wild type was significant as evaluated with an unpaired Student's *t*-test; $p < 0.05$. The dashed diagonals indicate the two-fold change, and the middle diagonal (black) represents the $x=y$ slope. (C) Detection of miR-51 by Northern Blotting in wild-type, *alg-1(0)*, *alg-1(S642A)* and *alg-1(S642E)* adult animals. The mature guide miRNA (miR-51) or passenger strand miRNA (miR-51*) are indicated as well as the precursor molecule (pre-miR-51). The detection of tRNA glycine (tRNA^{Gly}) was used as a loading control.

Representative images of two biological replicates. **(D)** Guide and passenger miRNA strands quantification by RT-qPCR. The levels of the guide and passenger strands of miR-71 and miR-238 in *alg-1(S642A)* and *alg-1(S642E)* gravid adult animals were measured by RT-qPCR and normalized to the levels of wild-type animals. Small nucleolar RNA sn2841 was used as an internal control gene. The error bars represent the 95% confidence interval from three biological replicates and the *P*-values were calculated using a two-tailed Student's *t*-test; * $p < 0.05$, ** $p < 0.01$.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 5. Phospho-mimicking ALG-1 S642E impairs binding to miRNAs.

(A) ALG-1 immunoprecipitation (IP) and small RNA sequencing experiments using wild-type (WT) and phosphorylation mutants animal populations. The plot shows the cumulative distribution of the \log_2 -fold changes ($\log_2(\text{FC})$) for miRNA reads in ALG-1 mutants IP vs ALG-1 WT IP averaged over three biological replicates. ALG-1 S642A mutant bind miRNAs similarly to ALG-1 WT (Blue). The ALG-1 S642E mutant binds far less miRNAs compared to WT (Red). The vertical line at 0 represents a $\log_2\text{FC}$ of zero compared to WT. (B) miR-35 miRISC pulldown of ALG-1. Proteins bound to miR-35 miRNA in gravid adult extracts were pulled-down using a 2'-O-methylated and 5' biotinylated RNA fully complementary oligonucleotide. The levels of ALG-1 pulled down in wild-type (WT) animal extracts or in phosphorylation mutants S642A and S642E were evaluated by western blotting. The ALG-1 levels in the input and in the pulldown relative to the signal in WT are shown. Representative image of three biological replicates. (C) Scatterplot of miRNA bound to ALG-1 averaged on three biological replicates and expressed as Log_2 of reads per million (RPM). The guide strands (Left) and passenger strands (miR*) (Right) associated to ALG-1 are plotted comparing ALG-1 S642E and ALG-1 WT. The dashed lines indicate the two-fold change, and the middle diagonal represents the $x=y$ slope. Red squares indicate miRNAs for which the number of reads were significantly different between WT and S642E IP, as determined with an unpaired Student's *t*-test ($p < 0.05$). miRNA reads obtained from ALG-1

IP were normalized on the number of miR-48-5p reads in each replicate as miR-48 binding to ALG-1 WT, ALG-1 S642A and ALG-1 S642E is robustly identical (Figure S5A).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 6. Protein Kinase A (PKA) genetically interacts with *alg-1* and *alg-1(S642A)*.

(A) Schematic of PKA activation. The consensus sequences for PKA substrates are shown on ALG-1 sequence for serine 642 (Top). The basic side chain of arginine (R) (Red) is commonly found at position -2 and -3 of PKA substrates. PKA is a holoenzyme complex (Bottom) formed by two regulatory subunits and two catalytic subunits: KIN-1 and KIN-2 respectively in *C. elegans*. Activation of GPCRs and downstream synthesis of cyclic adenosine monophosphate (cAMP) by adenylate cyclase leads to the dissociation of the complex which allows the catalytic subunit to phosphorylate its substrates. (B) ALG-1 peptides are phosphorylated *in vitro* by PKA at serine 642. The graph indicates the incorporation of ³²P as measured with a liquid scintillation counter following the incubation of peptides with recombinant PKA. 18 amino-acid peptides of ALG-1 spanning the S642 phosphorylation site or a peptide in which the serine (S) is replaced with an alanine (A) were used. The error bars show the 95% confidence interval from three independent experiments ($n=3$). (C) Autoradiogram and Coomassie blue stained gels of *in vitro* PKA kinase reaction. (D) Alae defects caused by *kin-2* RNAi are suppressed by the non-phosphorylatable mutant

alg-1(S642A). First stage larvae L1 were fed with bacteria expressing double-stranded RNA targeting *kin-2* mRNA or a control double-stranded RNA. Young adults staged wild-type animals or *alg-1(S642A)* mutants were monitored for alae defects. The *p*-value was measured by Fisher's exact test. The graph is representative of three biological replicates. (E) *alg-1(S642A)* suppresses *kin-2* loss of function mutant Bag of worms phenotype in *alg-2(0)* animals. The hypomorphic point mutation *kin-2(R92C)* was edited with CRISPR-Cas9 in *alg-2(0)* mutant and in the double mutant *alg-2(0);alg-1(S642A)*. The double mutant *alg-2(0); kin-2(R92C)* animals die at adult stage caused by a defect in egg laying (Egl) leading to embryos hatching inside the worm (Bag of worms). This phenotype was significantly suppressed in animals that cannot be phosphorylated on ALG-1 serine 642. The sample size (*n*=) used for quantification for each genotype is indicated and the *p*-value was calculated with Fisher's exact test.

Key resources table

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Mouse Anti-beta Actin Monoclonal Antibody, HRP Conjugated, Clone AC-15	Abcam	Cat# ab49900, RRID:AB_867494
Peroxidase-AffiniPure Goat Anti-Rabbit IgG (H+L) (min X Hu,Ms,Rat Sr Prot) antibody	Jackson Immunoresearch Labs.	Cat# 111-035-144, RRID:AB_2307391
Rabbit Anti-ALG-1 polyclonal antibody	(Vasquez-Rifo et al., 2012)	N/A
Rabbit Anti-AIN-1 polyclonal antibody	(Jannot et al., 2016)	N/A
Rabbit Anti-DCR-1 polyclonal antibody	(Duchaine et al., 2006)	N/A
Mouse Anti-Ubiquitin Antibody (P4D1) monoclonal antibody	Santa Cruz	Cat# sc-8017, RRID:AB_628423
Mouse Anti-HA.11 Monoclonal Antibody, Unconjugated, Clone 16B12	Covance	Cat# MMS-101P-500, RRID:AB_291261
IRDye 800CW Goat anti-Mouse IgG	Li-Cor Biosciences	Cat# 925-32210, RRID: AB_2687825
Bacterial and virus strains		
<i>E. coli</i> strain: OP50	Caenorhabditis Genetics Center	CGC: OP50, RRID: WB-STRAIN:WBStrain00041969
<i>E. coli</i> strain: HT115(DE3)	Caenorhabditis Genetics Center	CGC: HT115(DE3), RRID: WB-STRAIN:WBStrain00041080
Chemicals, peptides, and recombinant proteins		
Biotin-MFTNQLQRISNDAGMPIV-OH	This study	N/A
Biotin-MFTNQLQRIANDAGMPIV-OH	This study	N/A
Firefly D-Luciferin	PJK GmbH	Cat# 102111
MG-132	Sigma-Aldrich	Cat# 474790
Tri Reagent	Sigma-Aldrich	Cat# T9424
Critical commercial assays		
TaqMan Universal PCR Master Mix, no AmpErase UNG	Thermo Fisher Scientific	Cat# 4324018
Taqman MicroRNA Assay	Thermo Fisher Scientific	Cat# 4440886
Q5 Site-Directed Mutagenesis Kit	New England Biolabs	Cat# E0554S
Dynabeads M-280 Streptavidin	Thermo Fisher Scientific	Cat# 11205D
Dynabeads Protein G for Immunoprecipitation	Thermo Fisher Scientific	Cat# 10004D
Anti-FLAG M2 Magnetic Beads	Sigma Aldrich	Cat# M8823
High-Capacity cDNA Reverse Transcription Kit	Thermo Fisher Scientific	Cat# 4368814
Edit-R tracrRNA	Horizon Discovery	Cat# U-002005
Edit-R crRNA	Horizon Discovery	Cat# Custom0280
QIAseq miRNA Library Kit	Qiagen	Cat# 331505
Takyon No Rox SYBR MasterMix dTTP Blue	Eurogentec	Cat# UF-NSMT-B0701
Deposited data		
Small RNA sequencing reads from <i>Caenorhabditis elegans</i> adult worms (total RNA and ALG-1 IP)	This study	GEO: GSE198352
Small RNA sequencing reads at different time points during larval development	This study	GEO: GSE174368
Experimental models: Cell lines		

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Human: HEK293T cells	ATCC	RRID:CVCL_0063
Experimental models: Organisms/strains		
Strain N2 Bristol (WT)	<i>Caenorhabditis</i> Genetics Center	CGC: N2, RRID:WB-STRAIN:WBStrain00000001
Strain VC446: <i>alg-1(gk214) X</i>	<i>Caenorhabditis</i> Genetics Center	CGC: VC446, RRID: WB-STRAIN: WBStrain00035775
Strain KG532: <i>kin-2(ce179) X</i>	<i>Caenorhabditis</i> Genetics Center	CGC: KG532, RRID:WB-STRAIN:WBStrain00023482
Strain MJS218: <i>alg-1(gk214) Ex[alg-1p::lambdaN::mCherry::alg-1::alg-1 3'UTR; prf4(rol-6(su1006))]</i>	(Quévillon Huberdeau et al., 2017)	N/A
Strain MJS258: <i>alg-1(gk214) Ex[λN::mcherry::alg-1(S642E); prf4(rol-6(su1006))]</i>	This paper	N/A
Strain MJS259: <i>alg-1(gk214) Ex[λN::mcherry::alg-1(S642A); prf4(rol-6(su1006))]</i>	This paper	N/A
Strain MJS275: <i>alg-1(qbc23[S642A]) X</i>	This paper	N/A
Strain MJS306: <i>alg-1(qbc46[S642E]) X</i>	This paper	N/A
Strain HW1939: <i>xeSi296[Peft-3::luc::gfp::unc-54 3'UTR, unc-119(+)] II</i>	(Meeuse et al., 2020)	N/A
Strain HW3060: <i>xeSi296[Peft-3::luc::gfp::unc-54 3'UTR, unc-119(+)] II; alg-1(qbc23[S642A]) X</i>	This paper	N/A
Strain HW3061: <i>xeSi296[Peft-3::luc::gfp::unc-54 3'UTR, unc-119(+)] II; alg-1(qbc46[S642E]) X</i>	This paper	N/A
Strain MJS237: <i>qbcSi03[Palg-1::GFP::cog-1-boxb-cb-unc-119(+)] IV; alg-1(qbc18[lambdaN::alg-1]) X</i>	(Quévillon Huberdeau et al., 2017)	N/A
Strain MJS345: <i>qbcSi03[alg-1p::GFP::cog-1-boxb-cb-unc-119(+)] IV; alg-1(qbc66[λN::alg-1(S642E)]) X</i>	This paper	N/A
Strain MJS349: <i>qbcSi03[alg-1p::GFP::cog-1-boxb-cb-unc-119(+)] IV; alg-1(qbc67[λN::alg-1(S642A)]) X</i>	This paper	N/A
Strain MJS446: <i>alg-2(ok304) II; kin-2(qbc92[R92C]) X</i>	This paper	N/A
Strain MJS 447: <i>alg-2(ok304) II; kin-2(qbc92[R92C]) alg-1(qbc67[S642A]) X</i>	This paper	N/A
Oligonucleotides		
Primers used for cloning are listed in Table S2.	This study	N/A
CRISPR RNA and repair templates to generate <i>alg-1(S642A)</i> , <i>alg-1(S642E)</i> , <i>alg-1(Y693E)</i> and <i>kin-2(R92C)</i> are listed in Table S2.	This study	N/A
Primers for RT-qPCR are listed in Table S2.	This study	N/A
Recombinant DNA		
Plasmid L4440: untargeted RNAi vector	Addgene	Cat# 1654
Plasmid MSP163: RNAi vector targeting <i>alg-2</i>	(Bouasker and Simard, 2012)	N/A
Plasmid MSP437: RNAi vector targeting <i>kin-2</i>	This paper	N/A
Plasmid MSP186: <i>alg-1p::lambdaN::mCherry::alg-1::alg-1 3'UTR</i>	Jannot et al. 2016	N/A
Plasmid MSP438: <i>alg-1p::lambdaN::mCherry::alg-1(S642A)::alg-1 3'UTR</i>	This study	N/A
Plasmid MSP439: <i>alg-1p::lambdaN::mCherry::alg-1(S642E)::alg-1 3'UTR</i>	This study	N/A
Software and algorithms		

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Bowtie (version 0.12.7)	Langmead, B. et al, 2009	http://bowtie-bio.sourceforge.net/index.shtml
Bowtie (version 1.2.2)	Langmead, B. et al, 2009	http://bowtie-bio.sourceforge.net/index.shtml
Cutadapt (version 2.3)	Martin, M. et al., 2011	https://cutadapt.readthedocs.io/en/v2.3/
Samtools (version 1.9)	Li, H. et al, 2009	https://sourceforge.net/projects/samtools/files/samtools/1.9/
HTSeq (version 0.11.2)	Anders, S. et al, 2015	https://htseq.readthedocs.io/en/master/
Image Lab	Bio-Rad	https://www.bio-rad.com/en-ca/product/image-lab-software?ID=KRE6P5E8Z
Other		
Breathable sealing membrane (Breathe-EASIER)	Diversified Biotech	Cat# BERM-2000
Luminometer	Berthold Technologies	Centro XS3 LB 960
Gel Imaging System	Bio-Rad	ChemiDoc XRS+ System

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript